0001104659-19-060125.txt : 20191105 0001104659-19-060125.hdr.sgml : 20191105 20191105172057 ACCESSION NUMBER: 0001104659-19-060125 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 41 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191105 DATE AS OF CHANGE: 20191105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DFB Healthcare Acquisitions Corp. CENTRAL INDEX KEY: 0001725255 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 823677704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38399 FILM NUMBER: 191194337 BUSINESS ADDRESS: STREET 1: 300 CENTRAL PARK WEST STREET 2: 7G CITY: NEW YORK STATE: NY ZIP: 10024 BUSINESS PHONE: 917-359-3042 MAIL ADDRESS: STREET 1: 300 CENTRAL PARK WEST STREET 2: 7G CITY: NEW YORK STATE: NY ZIP: 10024 10-Q 1 a19-17611_110q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2019

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-38399

DFB HEALTHCARE ACQUISITIONS CORP.

(Exact name of registrant as specified in its charter)

Delaware		82-3677704
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

780 Third Avenue, New York, NY		10017
(Address of principal executive offices)		(Zip Code)

(212) 551-1600

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one share of Common Stock and one-third of one Warrant	DFBHU	The Nasdaq Stock Market LLC
Common Stock, par value $0.0001 per share	DFBH	The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50	DFBHW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	x	Smaller reporting company	x
		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes x No o

As of November 5, 2019, 31,250,000 shares of the Company’s common stock, par value $0.0001 per share, were issued and outstanding.

Table of Contents

DFB HEALTHCARE ACQUISITIONS CORP.

Form 10-Q

For the Quarter Ended September 30, 2019

Table of Contents

		Page No.
PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements

	Condensed Consolidated Balance Sheets as of September 30, 2019 (Unaudited) and December 31, 2018	1

	Unaudited Condensed Consolidated Interim Statements of Operations for the three and nine months ended September 30, 2019 and 2018	2

	Unaudited Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2019 and 2018	3

	Unaudited Condensed Consolidated Interim Statements of Cash Flows for the nine months ended September 30, 2019 and 2018	4

	Notes to Unaudited Condensed Consolidated Interim Financial Statements	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21

Item 4.	Controls and Procedures	21

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	21

Item 1A.	Risk Factors	21

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22

Item 3.	Defaults Upon Senior Securities	22

Item 4.	Mine Safety Disclosures	22

Item 5.	Other Information	22

Item 6.	Exhibits	23

SIGNATURES		24

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

DFB HEALTHCARE ACQUISITIONS CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2019		December 31, 2018
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	622,162	$	947,098
Prepaid expenses	124,468		158,005
Total current assets	746,630		1,105,103
Cash and marketable securities held in Trust Account	255,880,268		253,019,179
Total assets	$	256,626,898	$	254,124,282

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	28,675	$	40,774
Accrued expenses	3,125,000		500,379
Franchise tax payable	44,697		158,240
Total current liabilities	3,198,372		699,393
Deferred underwriting commissions	7,875,000		7,875,000
Total liabilities	11,073,372		8,574,393

Commitments and Contingencies
Common stock, $0.0001 par value; 24,055,352 and 24,054,988 shares subject to possible redemption at September 30, 2019 and December 31, 2018, respectively	240,553,520		240,549,880

Stockholders’ Equity:
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding	—		—
Common stock, $0.0001 par value; 200,000,000 shares authorized; 7,194,648 and 7,195,012 shares issued and outstanding (excluding 24,055,352 and 24,054,988 shares subject to possible redemption) at September 30, 2019 and December 31, 2018, respectively	719		720
Additional paid-in capital	2,910,249		2,913,888
Retained earnings	2,089,038		2,085,401
Total stockholders’ equity	5,000,006		5,000,009
Total Liabilities and Stockholders’ Equity	$	256,626,898	$	254,124,282

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

Table of Contents

DFB HEALTHCARE ACQUISITIONS CORP.

UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS

	For The Three Months Ended September 30,						For The Nine Months Ended September 30,
	2019			2018			2019			2018
General and administrative expenses	$	1,195,246		$	391,160		$	3,285,654		$	604,502
State franchise taxes	50,000			53,591			149,915			147,181
Loss from operations	(1,245,246		)	(444,751		)	(3,435,569		)	(751,683		)
Interest income	1,367,434			1,204,828			4,313,561			2,726,376
Income before income tax expense	122,188			760,077			877,992			1,974,693
Income tax expense	276,661			241,760			874,355			546,213
Net (loss) income	$	(154,473	)	$	518,317		$	3,637		$	1,428,480

Basic and diluted weighted average Public Shares (Note 3) outstanding	25,000,000			25,000,000			25,000,000			25,000,000
Basic and diluted net income per Public Share	$	0.04		$	0.03		$	0.13		$	0.07
Basic and diluted weighted average Founder Shares (Note 4) outstanding	6,250,000			6,250,000			6,250,000			6,250,000
Basic and diluted net loss per Founder Share	$	(0.19	)	$	(0.02	)	$	(0.53	)	$	(0.06	)

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

Table of Contents

DFB HEALTHCARE ACQUISITIONS CORP.

UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

	For the nine months ended September 30, 2019
						Additional						Total
	Common Stock					Paid-in						Stockholders’
	Shares		Amount			Capital			Retained Earnings			Equity
Balance - December 31, 2018	7,195,012		$	720		$	2,913,888		$	2,085,401		$	5,000,009
Common stock subject to possible redemption	(82,560	)	(9		)	(825,591		)	—			(825,600		)
Net income	—		—			—			825,598			825,598
Balance - March 31, 2019 (unaudited)	7,112,452		$	711		$	2,088,297		$	2,910,999		$	5,000,007
Common stock subject to possible redemption	66,749		7			667,483			—			667,490
Net loss	—		—			—			(667,488		)	(667,488		)
Balance - June 30, 2019 (unaudited)	7,179,201		$	718		$	2,755,780		$	2,243,511		$	5,000,009
Common stock subject to possible redemption	15,447		1			154,469			—			154,470
Net loss	—		—			—			(154,473		)	(154,473		)
Balance - September 30, 2019 (unaudited)	7,194,648		$	719		$	2,910,249		$	2,089,038		$	5,000,006

	For the nine months ended September 30, 2018
						Additional			Retained Earnings			Total
	Common Stock					Paid-in			(Accumulated			Stockholders’
	Shares		Amount			Capital			Deficit)			Equity
Balance - December 31, 2017	7,187,500		$	719		$	24,281		$	(693	)	$	24,307
Sale of units in initial public offering, net of offering costs	25,000,000		2,500			236,936,988			—			236,939,488
Sale of private placement warrants to Sponsor in private placement	—		—			6,500,000			—			6,500,000
Common stock subject to possible redemption	(23,868,412	)	(2,387		)	(238,681,733		)	—			(238,684,120		)
Net income	—		—			—			220,333			220,333
Balance - March 31, 2018 (unaudited)	8,319,088		832			4,779,536			219,640			5,000,008
Founder shares forfeited	(937,500	)	(94		)	94			—			—
Common stock subject to possible redemption	(68,983	)	(7		)	(689,823		)	—			(689,830		)
Net income	—		—			—			689,830			689,830
Balance - June 30, 2018 (unaudited)	7,312,605		731			4,089,807			909,470			5,000,008
Common stock subject to possible redemption	(51,832	)	(5		)	(518,315		)	—			(518,320		)
Net income	—		—			—			518,317			518,317
Balance - September 30, 2018 (unaudited)	7,260,773		$	726		$	3,571,492		$	1,427,787		$	5,000,005

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

Table of Contents

DFB HEALTHCARE ACQUISITIONS CORP.

UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

	For The Nine Months Ended September 30,
	2019			2018
Cash Flows from Operating Activities:
Net income	$	3,637		$	1,428,480
Adjustments to reconcile net income to net cash used in operating activities:
Interest income in cash and marketable securities held in Trust Account	(4,309,622		)	(2,726,376		)
Changes in operating assets and liabilities:
Prepaid expenses	33,537			(240,037		)
Accounts payable	(12,099		)	(46,400		)
Accrued expenses	2,624,621			202,217
Franchise tax payable	(113,543		)	112,212
Net cash used in operating activities	(1,773,469		)	(1,269,904		)

Cash Flows from Investing Activities:
Principal deposited in Trust Account	—			(250,000,000		)
Interest released from Trust Account	1,448,533			665,756
Net cash provided by (used in) investing activities	1,448,533			(249,334,244		)

Cash Flows from Financing Activities:
Proceeds from notes payable to related parties	—			96,291
Repayment of notes payable to related parties	—			(270,531		)
Proceeds received from initial public offering	—			250,000,000
Payment of offering costs	—			(4,994,717		)
Proceeds received from private placement	—			6,500,000
Net cash provided by financing activities	—			251,331,043

Net change in cash and cash equivalents	(324,936		)	726,895

Cash and cash equivalents - beginning of the period	947,098			119,821
Cash and cash equivalents - end of the period	$	622,162		$	846,716

Supplemental disclosure of noncash investing and financing activities:
Deferred underwriting commissions charged to equity in connection with the initial public offering	$	—		$	7,875,000
Deferred offering costs charged to equity upon completion of the initial public offering	$	—		$	190,795
Value of common stock subject to possible redemption	$	—		$	238,497,140
Change in value of common stock subject to possible redemption	$	3,640		$	876,810
Founder shares forfeited	$	—		$	94

Supplemental disclosures of cash flow information:
Cash paid for interest	$	—		$	—
Cash paid for income taxes	$	934,925		$	630,000

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

Table of Contents

DFB HEALTHCARE ACQUISITIONS CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Note 1—Description of Organization and Business Operations

DFB Healthcare Acquisitions Corp. (the “Company”) was incorporated in Delaware on November 22, 2017. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). Although the Company is not limited to a particular industry or sector for purposes of consummating a Business Combination, the Company intends to focus its search on the healthcare or healthcare related industries. The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.

As of September 30, 2019, the Company had not commenced any operations. All activity for the period from November 22, 2017 (inception) through September 30, 2019 relates to the Company’s formation, the Company’s initial public offering (the “Initial Public Offering”), and, since the closing of the Initial Public Offering, the search for a prospective initial Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering.

The Company’s sponsor is Deerfield/RAB Ventures, LLC, a Delaware limited liability company (the “Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on February 15, 2018. On February 21, 2018, the Company consummated its Initial Public Offering of 25,000,000 units (each, a “Unit” and collectively, the “Units”) sold to the public at the price of $10.00 per Unit, generating gross proceeds of $250 million and incurring offering costs of approximately $13.06 million, inclusive of $7.875 million in deferred underwriting commissions (Note 5). The underwriter was granted a 45-day option from the date of the final prospectus relating to the Initial Public Offering to purchase up to 3,750,000 additional Units to cover over-allotments, if any, at $10.00 per Unit. The over-allotment option was not exercised prior to its expiration on April 2, 2018.

Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (the “Private Placement”) of 4,333,333 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant to the Sponsor, generating gross proceeds of $6.5 million (Note 4). The Sponsor had agreed that, had the over-allotment option been exercised, the Sponsor would have purchased up to an additional 500,000 Private Placement Warrants at a price of $1.50 per Private Placement Warrant.

Upon the closing of the Initial Public Offering and the Private Placement, $250 million ($10.00 per Unit) of the net proceeds of the sale of the Units in the Initial Public Offering and the Private Placement was placed in a trust account (the “Trust Account”), located in the United States at J.P. Morgan Chase Bank, N.A., with Continental Stock Transfer & Trust Company acting as trustee, and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of paragraphs (d)(2), (d)(3) and (d)(4) of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below.

At September 30, 2019, the Company had approximately $622,000 in cash held outside of the Trust Account. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.

The Company will provide its holders of the outstanding shares of its common stock, par value $0.0001, sold in the Initial Public Offering (the “public stockholders”) with the opportunity to redeem all or a portion of their Public Shares (as defined below in Note 3) upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially at $10.00 per Public Share). The per-share amount to be distributed to public stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5). These Public Shares are recorded at a redemption value and classified as temporary equity in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business

Table of Contents

DFB HEALTHCARE ACQUISITIONS CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company decides not to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transactions is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the initial stockholders (as defined below) agreed to vote their Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. The Company’s insiders must: (i) refrain from purchasing shares during certain blackout periods and when they are in possession of any material non-public information and (ii) to clear all trades with the Company’s legal counsel prior to execution. In addition, the initial stockholders agreed to waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of a Business Combination.

Notwithstanding the foregoing, the Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the common stock sold in the Initial Public Offering, without the prior consent of the Company.

The Company’s Sponsor, officers and directors (the “initial stockholders”) agreed not to propose an amendment to the Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the public stockholders with the opportunity to redeem their shares of common stock in conjunction with any such amendment.

If the Company is unable to complete a Business Combination within 24 months from the closing of the Initial Public Offering, or February 21, 2020 (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest (less up to $50,000 of interest to pay dissolution expenses, which interest shall be net of taxes payable by the Company and any amounts released to the Company to fund working capital requirements, subject to an annual limit of $250,000), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.

The initial stockholders agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the initial stockholders should acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to their deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be less than the $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a definitive agreement for a Business Combination, reduce the amount of funds in the Trust Account to below (i) $10.00 per Public Share or (ii) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company has sought and will continue to seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

Table of Contents

DFB HEALTHCARE ACQUISITIONS CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

On July 8, 2019, the Company, AdaptHealth Holdings LLC, a Delaware limited liability company (“Adapt”), BM AH Holdings, LLC, a Delaware limited liability company, Access Point Medical, Inc., a Delaware corporation, DFB Merger Sub LLC, a Delaware limited liability company, AH Representative LLC, a Delaware limited liability company, and, solely for the limited purposes set forth therein, BlueMountain Foinaven Master Fund L.P., a Cayman Islands exempted limited partnership, BMSB L.P., a Delaware limited partnership, BlueMountain Fursan Fund L.P., a Cayman Islands exempted limited partnership, and Clifton Bay Offshore Investments, L.P., a British Virgin Islands limited partnership (collectively, the “Blocker Sellers”), entered into an Agreement and Plan of Merger (the “Agreement”), which was later amended on October 15, 2019, pursuant to which the Company agreed to combine with Adapt in a transaction (the “Transaction”) that will result in Adapt becoming a partially owned subsidiary of the Company. It is anticipated that the Company will change its name to AdaptHealth Corp. upon the consummation of the Transaction (Note 8).

Liquidity and Going Concern

In connection with the Company’s assessment of going concern considerations in accordance with FASB’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” the Company’s management has determined that the mandatory liquidation and subsequent dissolution raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after February 21, 2020.

Through September 30, 2019, the Company’s liquidity needs have been satisfied through receipt of a $25,000 capital contribution from the Sponsor in exchange for the issuance of the Founder Shares (Note 4) to the Sponsor, $270,531 in loans from the Sponsor (which was fully repaid on February 21, 2018), the proceeds from the consummation of the Private Placement not held in the Trust Account, and interest withdrawn from the Trust Account for working capital and tax purposes. The Company withdrew approximately $1.4 million and $666,000 of interest income from the Trust Account during the nine months ended September 30, 2019 and 2018, respectively to pay for tax obligations and working capital purposes. Of the $1.4 million of interest income withdrawn in 2019, $250,000 was for working capital.

As of September 30, 2019, the Company had approximately $622,000 in its operating bank account, and approximately $5.9 million of interest income available to fund a Business Combination (which interest shall be net of taxes payable by the Company and any amounts, subject to an annual limit of $250,000, released to the Company to fund working capital requirements), and a working capital deficit of approximately $2.4 million. In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”) (see Note 4). The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. Based on the foregoing, the Company may have insufficient funds available to operate its business through February 21, 2020. Following the initial Business Combination, if cash on hand is insufficient, the Company may need to obtain additional financing in order to meet its obligations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s plans to raise capital or to consummate the initial Business Combination may not be successful. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

Note 2—Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated interim financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ended December 31, 2019, or any future period. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited financial statements contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2019.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, DFB Merger Sub LLC, a Delaware limited liability company, formed on June 17, 2019. All significant intercompany balances and transactions have been eliminated in consolidation.

Table of Contents

DFB HEALTHCARE ACQUISITIONS CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Emerging Growth Company

Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.

This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. At September 30, 2019 and December 31, 2018, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had approximately $233,000 and $0 in cash equivalents as of September 30, 2019 and December 31, 2018, respectively.

Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented on the condensed consolidated balance sheets.

Use of Estimates

The preparation of the financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.

Offering Costs

Offering costs, which consist of legal, accounting, underwriting fees and other costs that were directly related to the Initial Public Offering, totaled approximately $13.06 million, inclusive of $7.875 million in deferred underwriting commissions. Offering costs were charged to stockholders’ equity upon the completion of the Initial Public Offering.

Common Stock Subject to Possible Redemption

The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Shares of common stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable shares of common stock (including shares of common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, shares of common stock are classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at September 30, 2019 and December 31, 2018, 24,055,352 and 24,054,988, respectively, shares of common stock subject to possible redemption at the redemption amount are presented as temporary equity, outside of the stockholders’ equity section of the Company’s condensed consolidated balance sheets.

Net Income (Loss) per Share

Net income (loss) per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the periods. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the

Table of Contents

DFB HEALTHCARE ACQUISITIONS CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Private Placement to purchase an aggregate of 12,666,666 shares of the Company’s common stock in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method.

The Company’s unaudited condensed consolidated interim statements of operations include a presentation of income per share for common stock subject to redemption in a manner similar to the two-class method of income per share. Net income per common share, basic and diluted for Public Shares is calculated by dividing the interest income earned on the Trust Account, net of applicable taxes and funds available to be withdrawn from the Trust Account for working capital purposes (subject to an annual limit of $250,000), resulting in a total of approximately $1.0 million and $3.3 million for the three and nine months ended September 30, 2019, respectively, by the weighted average number of Public Shares outstanding for the periods. Net loss per common share, basic and diluted for Founder Shares is calculated by dividing the net income, less income attributable to Public Shares by the weighted average number of Founder Shares outstanding for the periods.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of September 30, 2019 and December 31, 2018, the Company has a deferred tax asset of approximately $904,000 and $217,000 respectively, which has a full valuation allowance recorded against it.

The Company’s current taxable income primarily consists of interest income on the Trust Account. The Company’s general and administrative costs are generally considered start-up costs and are not currently deductible. During the three and nine months ended September 30, 2019 and 2018, the Company recorded income tax expense of approximately $277,000 and $874,000 in 2019, and approximately $242,000 and $546,000 in 2018, respectively, primarily related to interest income earned on the Trust Account. The Company’s effective tax rate for the nine months ended September 30, 2019 and 2018 was approximately 98.0% and 27.7%, respectively, which differs from the expected income tax rate due to the start-up costs (discussed above) which are not currently deductible.

FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2019 and December 31, 2018. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

Recent Accounting Pronouncements

The Company’s management does not believe that there are any recently issued, but not yet effective, accounting pronouncements, that, if currently adopted, would have a material effect on the Company’s unaudited condensed consolidated interim financial statements.

Note 3—Public Offering

On February 21, 2018, the Company sold 25,000,000 Units at a price of $10.00 per Unit in the Initial Public Offering. Each Unit consists of one share of common stock (such shares of common stock included in the Units being offered, the “Public Shares”), and one-third of one redeemable warrant (each, a “Public Warrant”). Each Public Warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment (see Note 6).

Note 4—Related Party Transactions

Founder Shares

On December 15, 2017, the Sponsor purchased 7,187,500 shares (the “Founder Shares”) of the Company’s common stock, par value $0.0001 for an aggregate price of $25,000. In December 2017 and January 2018, the Sponsor transferred 100,000 Founder Shares to Christopher Wolfe, the Company’s Chief Financial Officer, and 30,000 Founder Shares to each of Steven Hochberg, Dr. Susan Weaver, Dr. Mohit Kaushal and Dr. Gregory Sorensen, the Company’s independent directors. The initial stockholders agreed to forfeit up to 937,500 Founder Shares to the extent that the over-allotment option was not exercised in full by the underwriters. The forfeiture was to be adjusted to the extent that the over-allotment option was not exercised in full by the underwriters so that the Founder Shares

Table of Contents

DFB HEALTHCARE ACQUISITIONS CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

would represent 20.0% of the Company’s issued and outstanding shares after the Initial Public Offering. On April 2, 2018, the over-allotment option expired and an aggregate of 937,500 shares were subsequently forfeited by the initial stockholders.

The initial stockholders agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the last sale price of the common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Company’s stockholders having the right to exchange their shares of common stock for cash, securities or other property.

Private Placement Warrants

Concurrently with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 4,333,333 Private Placement Warrants at a price of $1.50 per Private Placement Warrant, generating gross proceeds of $6.5 million in the Private Placement. The Sponsor had agreed that if the over-allotment option was exercised, the Sponsor would have purchased up to an additional 500,000 Private Placement Warrants at a price of $1.50 per Private Placement Warrant, for additional gross proceeds of $750,000.

Each Private Placement Warrant is exercisable for one share of common stock at a price of $11.50 per share. The proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees.

The Sponsor and the Company’s officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Warrants until 30 days after the completion of the initial Business Combination.

An affiliate of Deerfield Management Company, L.P, a Delaware series limited partnership (“Deerfield Management”), which is a significant owner of the Sponsor, purchased 2,500,000 Units in the Initial Public Offering at $10.00 per Unit. The underwriters did not receive any underwriting discounts or commissions on the Units purchased by Deerfield Management’s affiliate.

Related Party Loans

The Sponsor loaned the Company an aggregate of $270,531 to cover expenses related to the Initial Public Offering and working capital needs. The loan was non-interest bearing. The Company repaid this loan on February 21, 2018.

In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company Working Capital Loans. If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. To date, the Company had no borrowings under the Working Capital Loans.

Services Agreements and Reimbursements

The Company entered into an agreement, commencing on February 16, 2018 through the earlier of the Company’s consummation of a Business Combination and its liquidation, to pay the Sponsor a total of $10,000 per month for office space, utilities and secretarial and administrative support.

The Company is obligated to pay $7,500 per month to Mr. Wolfe, the Company’s Chief Financial Officer, for his services prior to the consummation of the initial Business Combination, subject to the terms of the strategic services agreement.

The Sponsor, executive officers and directors, or any of their respective affiliates, will be reimbursed for any out-of-pocket expenses incurred in connection with activities on the Company’s behalf such as identifying potential target businesses and performing due diligence on suitable Business Combinations. The Company’s audit committee will review on a quarterly basis all payments that were

Table of Contents

DFB HEALTHCARE ACQUISITIONS CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

made to the Sponsor, officers, directors or their affiliates and will determine which expenses and the amount of expenses that will be reimbursed. There is no cap or ceiling on the reimbursement of out-of-pocket expenses incurred by such persons in connection with activities on the Company’s behalf.

The Company recorded an aggregate of $52,500 during the three months ended September 30, 2019 and 2018 each, and $157,500 and $130,000 during the nine months ended September 30, 2019 and 2018, respectively, in general and administrative expenses in connection with the related agreements in the accompanying unaudited condensed consolidated interim statements of operations.

Note 5—Commitments & Contingencies

Registration Rights

The holders of Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans, if any, and any shares of common stock underlying such securities, will be entitled to registration rights pursuant to a registration rights agreement entered into on February 15, 2018. These holders will be entitled to certain demand and “piggyback” registration rights. However, the registration rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until the termination of the applicable lock-up period for the securities to be registered. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The Company granted the underwriters a 45-day option from the date of the final prospectus relating to the Initial Public Offering to purchase up to 3,750,000 additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. The option expired on April 2, 2018.

The underwriters were entitled to an underwriting discount of $0.20 per Unit, or $4.5 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per Unit, or $7.875 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

The underwriters did not receive any underwriting discounts or commissions on the 2,500,000 Units purchased by Deerfield Management in the Initial Public Offering.

Note 6—Stockholders’ Equity

Common Stock—On February 15, 2018, the Company filed its Amended and Restated Certificate of Incorporation to increase its number of authorized common stock to 200,000,000 shares with a par value of $0.0001 per share. Holders of common stock are entitled to one vote for each share. As of September 30, 2019 and December 31, 2018, there were 31,250,000 shares of common stock outstanding, including 24,055,352 and 24,054,988 shares of common stock subject to possible redemption, respectively,

Preferred Stock—The Company is authorized to issue 1,000,000 shares of preferred stock, par value $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2019 and December 31, 2018, there were no shares of preferred stock issued or outstanding.

Warrants—Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable 30 days after the completion of a Business Combination; provided that the Company has an effective registration statement under the Securities Act covering the common stock issuable upon exercise of the Public Warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their Public Warrants on a cashless basis and such cashless exercise is exempt from registration under the Securities Act). The Company has agreed that as soon as practicable, but in no event later than 20 business days, after the closing of a Business Combination, the Company will use its best efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the common stock issuable upon exercise of the Public Warrants. The Company will use its best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the Public Warrants in accordance with the provisions of the warrant agreement. If a registration statement covering the common stock issuable upon exercise of the warrants is not effective by the sixtieth (60th) day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

Table of Contents

DFB HEALTHCARE ACQUISITIONS CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the common stock issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be non-redeemable so long as they are held by the initial purchasers or such purchasers’ permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

The Company may call the Public Warrants for redemption (except with respect to the Private Placement Warrants):

· in whole and not in part;

· at a price of $0.01 per warrant;

· upon a minimum of 30 days’ prior written notice of redemption; and

· if, and only if, the last reported sales price of the common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement.

The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrant shares. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

Note 7—Fair Value Measurements

The following table presents information about the Company’s assets that are measured on a recurring basis as of September 30, 2019 and December 31, 2018 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value.

September 30, 2019

	Quoted Prices		Significant Other	Significant Other
	in Active Markets		Observable Inputs	Unobservable Inputs
Description	(Level 1)		(Level 2)	(Level 3)
Cash and marketable securities held in Trust Account	$	255,880,268

December 31, 2018

	Quoted Prices		Significant Other	Significant Other
	in Active Markets		Observable Inputs	Unobservable Inputs
Description	(Level 1)		(Level 2)	(Level 3)
Cash and marketable securities held in Trust Account	$	253,019,179

Approximately $1,300 and $900 of the balance in the Trust Account was held in cash as of September 30, 2019 and December 31, 2018, respectively.

Note 8—Merger Agreement

On July 8, 2019, the Company, Adapt, BM AH Holdings, LLC, a Delaware limited liability company, Access Point Medical, Inc., a Delaware corporation, DFB Merger Sub LLC, a Delaware limited liability company, AH Representative LLC, a Delaware limited liability company, and, solely for the limited purposes set forth therein, BlueMountain Foinaven Master Fund L.P., a Cayman Islands exempted limited partnership, BMSB L.P., a Delaware limited partnership, BlueMountain Fursan Fund L.P., a Cayman Islands exempted limited partnership, and Clifton Bay Offshore Investments, L.P., a British Virgin Islands limited partnership, entered into the Agreement pursuant to which the Company agreed to combine with Adapt in a transaction that will result in Adapt becoming the Company’s partially owned subsidiary. The merger consideration, aggregating $515 million, consists of up to 51.5 million shares of common stock to be issued by the Company, except that holders of membership interests in Adapt and the Blocker Sellers have the right to receive

Table of Contents

DFB HEALTHCARE ACQUISITIONS CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

cash, not to exceed $50.0 million in the aggregate, at the closing of the Transaction, in which case the number of shares to be issued would be reduced by an amount equal to the total amount of cash consideration paid divided by $10.00. Founded in 2012 and headquartered in Plymouth Meeting, PA, Adapt offers a full suite of medical products for both rental and sale, with a focus on respiratory and/or mobility equipment, including CPAP sleep equipment, oxygen equipment, wheelchairs, walkers, and hospital beds. Adapt serves over 1.0 million patients and performs 7,000 deliveries per day across 49 states through more than 150 locations. The consummation of the Transaction is subject to a number of conditions set forth in the Agreement including, among others, receipt of the requisite approval of the Company’s stockholders and the execution of the various transaction agreements. It is anticipated that the Company will change its name to AdaptHealth Corp. upon the consummation of the Transaction.

In connection with the execution of the Agreement, the Company, Adapt and certain members of Adapt, entered into a lock-up agreement (the “Lock-up Agreement”). Under the terms of the Lock-up Agreement, such members agreed to certain lock-up arrangements with the Company, pursuant to which: (i) certain of such members will be restricted from selling, transferring or pledging any securities of the Company they receive in connection with the Transaction for a period of nine months from the closing of the Transaction and (ii) certain members of Adapt are restricted from selling, transferring or pledging such securities for a period of either six months or three months from the closing of the Transaction, depending upon whether such member has made a liquidity request as contemplated by Section 7.19 of the Agreement.

On July 8, 2019, the Company entered into a subscription agreement (the “Subscription Agreement”) with Deerfield Private Design Fund IV, L.P. (“Deerfield”), pursuant to which Deerfield agreed to purchase, and the Company agreed to sell to Deerfield, between 5,000,000 and 10,000,000 shares of common stock of the Company (the “PIPE Shares”), depending on the amount of cash available to the Company immediately prior to the consummation of the Transaction, for a purchase price of $10.00 per share, in a private placement. Deerfield also agreed that it would (i) continue to own, through the consummation of the Transaction, the 2.5 million shares of the Company’s common stock it purchased in the Company’s initial public offering; (ii) not exercise its redemption rights with respect to any of such shares; and (iii) vote such shares in favor of the Transaction and any other proposals of the Company set forth in the proxy statement to be filed by the Company in connection with the Transaction. The closing of the sale of the PIPE Shares will be contingent upon the substantially concurrent consummation of the Transaction and the satisfaction of other customary closing conditions. The PIPE Shares will be subject to a “lock-up” provision, pursuant to which they may not be sold or otherwise transferred for a period of nine months after the closing date of the Subscription Agreement. Deerfield will have registration rights with respect to the PIPE Shares pursuant to the terms of a registration rights agreement. No fees or other compensation was paid or will be payable to Deerfield or any third parties in consideration of Deerfield entering into the Subscription Agreement. Following the date of the Agreement, subject to the terms and conditions of the Agreement, the Company may enter into additional PIPE subscription agreements.

In connection with the Transaction, the Company, Adapt, and the Sponsor entered into a letter agreement (the “Assignment Letter Agreement”) pursuant to which the Sponsor will, immediately prior to the consummation of the Transaction, transfer and assign to Adapt (or such other equityholder or employee of Adapt as Adapt may designate prior to the consummation of the Transaction), 2,500,000 shares of the Company’s common stock and 1,733,333 warrants to purchase shares of the Company’s common stock (with each warrant exercisable for one-third of a share of the Company’s common stock).

On October 15, 2019, the Company entered into Amendment No. 1 (the “Amendment”) to the Agreement which, among other things, (i) removes the minimum cash closing condition contained in the Agreement, (ii) adds a new condition to the closing of the Transaction (the “Closing”) with respect to the absence, since the date of the Amendment, of the commencement of an investigation, review or other action concerning a material violation of healthcare law against Adapt by certain regulatory authorities, (iii) adds a provision obligating the Clifton Bay Offshore Investments, L.P. to indemnify the Company against liabilities of the Access Point Medical, Inc., including tax liabilities, arising prior to the Closing and (iv) amend and restate the forms of the amended and restated certificate of incorporation of the Company to be adopted at the Closing and of the tax receivables agreement to be entered into at the Closing.

Table of Contents

DFB HEALTHCARE ACQUISITIONS CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Shares to be purchased will equal 10,000,000. If the Available Cash is more than $200 million, then the total number of PIPE Shares to be purchased will be such number of shares of the Company’s common stock (rounded up to the nearest whole number) equal to (A) $300 million minus the amount of Available Cash, divided by (B) ten; provided that in no event will the number of shares purchased be less than 5,000,000. If the total number of PIPE Shares to be purchased is 10,000,000 or less, then Deerfield will purchase all of the PIPE Shares, and if the total number of PIPE Shares to be purchased is more than 10,000,000, then Deerfield will purchase 10,000,000 of the PIPE Shares plus 96% of the PIPE Shares in excess of 10,000,000, and RAB Ventures will purchase the remaining PIPE Shares. RAB Ventures is an entity that is controlled by Richard Barasch, the Company’s President, Chief Executive Officer and Chairman and is one of the members of the Sponsor. Pursuant to the A&R Subscription Agreement, the PIPE Shares will be subject to a “lock-up” provision, pursuant to which they may not be sold or otherwise transferred for a period of time following the Closing. The term of such lock-up period will be nine months for 7,500,000 PIPE Shares purchased by Deerfield, and three months for any other PIPE Shares purchased in excess of that amount by either Deerfield or RAB Ventures. Deerfield (and RAB Ventures, if it purchases any PIPE Shares) will have registration rights with respect to the PIPE Shares pursuant to the terms of a registration rights agreement.

In connection with the Amendment, on October 15, 2019, the Company, Adapt and the Sponsor entered into an amended and restated letter agreement (the “A&R Assignment Letter Agreement”), which amends and restates in its entirety the Assignment Letter Agreement. Pursuant to the A&R Assignment Letter Agreement, the Sponsor will, immediately prior to the Closing, transfer and assign to Adapt (or such equityholders or employees of Adapt as Adapt may designate prior to the Closing), for no consideration, between 2,437,500 and 2,500,000 of the shares of the Company’s common stock and between 1,690,000 and 1,733,333 of the warrants to purchase shares of the Company’s common stock held by the Sponsor. The number of shares and warrants to be transferred will be determined based on the number of PIPE Shares purchased pursuant to the A&R Subscription Agreement. If the number of PIPE Shares purchased is 10,000,000 or less, then 2,500,000 shares and 1,733,333 warrants will be transferred. If the number of PIPE Shares purchased is 12,500,000, then 2,437,500 shares and 1,690,000 warrants will be transferred. If the number of PIPE Shares is more than 10,000,000 but less than 12,500,000, then the number of shares and warrants will be calculated on a pro rata basis, based on the number of PIPE Shares purchased in excess of 10,000,000. A portion of the shares to be transferred pursuant to the A&R Assignment Letter Agreement may be transferred by the Company’s executive officers and/or directors instead of the Sponsor.

In connection with the proposed Transaction, the Company filed a preliminary proxy statement with the SEC relating to the Transaction on August 19, 2019. the Company subsequently filed Amendment No. 1 and Amendment No. 2 to the preliminary proxy statement with the SEC on September 24, 2019 and Amendment No. 3 to the preliminary proxy statement on October 15, 2019. The Company filed the definitive proxy statement with the SEC relating to the Transaction on October 23, 2019 and mailed it to the Company’s stockholders on October 25, 2019.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

References in this report (the “Quarterly Report”) to “we”, “us”, “our” or the “Company” are to DFB Healthcare Acquisitions Corp., except where the context requires otherwise. References to our “management” or our “management team” are to our officers and directors, and references to the “Sponsor” are to Deerfield/RAB Ventures, LLC. The following discussion should be read in conjunction with our condensed consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other Securities and Exchange Commission (“SEC”) filings. The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. All subsequent written or oral forward-looking statements attributable to us or persons acting on the Company’s behalf are qualified in their entirety by this paragraph.

Overview

We are a blank check company incorporated as a Delaware corporation on November 22, 2017 and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (“Business Combination”). Although we are not limited to a particular industry or sector for purposes of consummating a Business Combination, we have initially focused our search on the healthcare or healthcare related industries.

The registration statement for our initial public offering (“Initial Public Offering”) was declared effective on February 15, 2018. On February 21, 2018, we consummated our Initial Public Offering of 25,000,000 units (“Units”) sold to the public at the price of $10.00 per Unit, generating gross proceeds of $250,000,000. Each Unit consists of one share of common stock and one-third of one redeemable warrant, each whole warrant entitling the holder to purchase one share of common stock at an exercise price of $11.50 per share, subject to adjustment. The underwriters were granted a 45-day option to purchase up to 3,750,000 additional Units to cover over-allotments, if any, at $10.00 per Unit. The over-allotment option was not exercised prior to its expiration on April 2, 2018.

Simultaneously with the consummation of our Initial Public Offering, we consummated a private placement (the “Private Placement”) of 4,333,333 warrants (“Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant to our Sponsor, generating total proceeds of $6,500,000. Following our Initial Public Offering and the Private Placement, and after deducting offering expenses, $250,000,000 (including $7,875,000 of deferred underwriting commissions) were placed in a trust account located in the United States at J.P. Morgan Chase Bank, N.A., with Continental Stock Transfer & Trust Company acting as trustee (the “Trust Account”).

If we are unable to complete a Business Combination by February 21, 2020, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest (less up to $50,000 of interest to pay dissolution expenses, which interest shall be net of taxes payable by us and any amounts released to us to fund working capital requirements, which such working capital is subject to an annual limit of $250,000), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject in each case to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.

On July 8, 2019, we, AdaptHealth Holdings LLC, a Delaware limited liability company (“Adapt”), BM AH Holdings, LLC, a Delaware limited liability company, Access Point Medical, Inc., a Delaware corporation, DFB Merger Sub LLC, a Delaware limited liability company, AH Representative LLC, a Delaware limited liability company, and, solely for the limited purposes set forth therein, BlueMountain Foinaven Master Fund L.P., a Cayman Islands exempted limited partnership, BMSB L.P., a Delaware limited partnership, BlueMountain Fursan Fund L.P., a Cayman Islands exempted limited partnership, and Clifton Bay Offshore Investments, L.P., a British Virgin Islands limited partnership (collectively, the “Blocker Sellers”), entered into an Agreement and Plan of Merger (the “Agreement”), which was later amended on October 15, 2019, pursuant to which we agreed to combine with Adapt in a transaction (the

Table of Contents

“Transaction”) that will result in Adapt becoming a partially owned subsidiary of our company. It is anticipated that we will change its name to AdaptHealth Corp. upon the consummation of the Transaction.

Results of Operations

Our entire activity since November 22, 2017 (inception) through September 30, 2019 was in preparation for our Initial Public Offering, and since our Initial Public Offering, our activity has been limited to the search for a prospective initial Business Combination. We will not be generating any operating revenues until the closing and completion of our initial Business Combination. We have increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.

For the three months ended September 30, 2019, we had net loss of approximately $154,000, which consisted of approximately $1.4 million of interest income, offset by approximately $1.2 million in general and administrative expenses, $50,000 in franchise tax expense, and approximately $277,000 in income tax expense. Of the $1.2 million in general and administrative expenses, approximately $972,000 was in connection with the Transaction.

For the nine months ended September 30, 2019, we had net income of approximately $3,600, which consisted of approximately $4.3 million in interest income, offset by approximately $3.3 million in general and administrative expenses, approximately $150,000 in franchise tax expense, and approximately $874,000 in income tax expense. Of the $3.3 million in general and administrative expenses, approximately $2.6 million was in connection with the Transaction.

For the three months ended September 30, 2018, we had net income of approximately $518,000, which consisted of approximately $1.2 million in interest income, offset by approximately $391,000 in general and administrative costs, $54,000 in franchise tax expense, and $242,000 in income tax expense.

For the nine months ended September 30, 2018, we had net income of approximately $1.4 million, which consisted of approximately $2.7 million in interest income, offset by approximately $605,000 in general and administrative costs, $147,000 in franchise tax expense, and $546,000 in income tax expense.

Liquidity and Going Concern

In connection with our management’s assessment of going concern considerations in accordance with the Financial Accounting Standards Board’s Accounting Standards Update 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” our management has determined that the mandatory liquidation and subsequent dissolution raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should we be required to liquidate after February 21, 2020.

Through September 30, 2019, our liquidity needs have been satisfied through receipt of a $25,000 capital contribution from our Sponsor in exchange for the issuance of the Founder Shares (defined below) to our Sponsor, $270,531 in loans from our Sponsor, the proceeds from the consummation of the Private Placement not held in the Trust Account, and interest withdrawn from the Trust Account for working capital and tax purposes. We withdrew approximately $1.4 million and $666,000 of interest income from the Trust Account during the nine months ended September 30, 2019 and 2018, respectively to pay for tax obligations and working capital purposes. Of the $1.4 million of interest income withdrawn in 2019, $250,000 was for working capital.

Following our Initial Public Offering and the Private Placement, $250,000,000 was placed in the Trust Account, including $7,875,000 of deferred underwriting commissions. We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (which interest shall be net of taxes payable by us and any amounts released to us to fund working capital requirements, subject to an annual limit of $250,000, and excluding deferred underwriting commissions) to complete our initial Business Combination. We may withdraw interest to pay taxes and fund working capital requirements (subject to an annual limit of $250,000 for withdrawals to fund working capital requirements). To the extent that our equity or debt is used, in whole or in part, as consideration to complete our initial Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

We intend to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, structure, negotiate and complete a Business Combination, and to pay taxes to the extent the interest earned on the Trust Account is not sufficient to pay our taxes.

As indicated in the accompanying financial statements, as of September 30, 2019, we had approximately $622,000 in our operating bank account, and approximately $5.9 million of interest income available (which interest shall be net of taxes payable by us and any

Table of Contents

amounts, subject to an annual limit of $250,000, released to us to fund working capital requirements), and a working capital deficit of approximately $2.4 million. In order to finance transaction costs in connection with a Business Combination, our Sponsor or an affiliate of our Sponsor, or certain of our officers and directors may, but are not obligated to, loan us funds as may be required (“Working Capital Loans”). We have incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. Based on the foregoing, we may have insufficient funds available to operate our business through February 21, 2020. Following the initial Business Combination, if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations. We cannot be certain that additional funding will be available on acceptable terms, or at all. Our plans to raise capital or to consummate the initial Business Combination may not be successful. These matters, among others, raise substantial doubt about our ability to continue as a going concern.

Related Party Transactions

Founder Shares

In December 2017, our Sponsor purchased an aggregate of 7,187,500 shares of our common stock, par value $0.0001 per share, for an aggregate purchase price of $25,000 (the “Founder Shares”). In December 2017 and January 2018, our Sponsor transferred 100,000 Founder Shares to Christopher Wolfe, our Chief Financial Officer, and 30,000 Founder Shares to each of our independent directors. Following the expiration of the underwriters’ over-allotment option on April 2, 2018, the holders of the Founder Shares forfeited an aggregate of 937,500 Founder Shares, so that the Founder Shares would represent 20.0% of our issued and outstanding shares after our Initial Public Offering.

Our Sponsor and our officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the last sale price of the common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which we complete a liquidation, merger, capital stock exchange or other similar transaction that results in all of our stockholders having the right to exchange their shares of common stock for cash, securities or other property.

Private Placement Warrants

Concurrently with the closing of our Initial Public Offering, our Sponsor purchased an aggregate of 4,333,333 Private Placement Warrants at a price of $1.50 per Private Placement Warrant, generating gross proceeds of $6,500,000 in the Private Placement. Our Sponsor had agreed that if the over-allotment option was exercised, our Sponsor would have purchased up to an additional 500,000 Private Placement Warrants at a price of $1.50 per Private Placement Warrant, for additional gross proceeds of $750,000.

Each Private Placement Warrant is exercisable for one share of common stock at a price of $11.50 per share. The proceeds from the Private Placement Warrants were added to the proceeds from our Initial Public Offering held in the Trust Account. If we do not complete a Business Combination by February 21, 2020, the Private Placement Warrants will expire worthless. The Private Placement Warrants are non-redeemable and exercisable on a cashless basis so long as they are held by our Sponsor or its permitted transferees.

Our Sponsor and our officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Warrants until 30 days after the completion of the initial Business Combination.

An affiliate of Deerfield Management Company, L.P, a Delaware series limited partnership (“Deerfield Management”), which is a significant owner of our Sponsor, purchased 2,500,000 Units in our Initial Public Offering at $10.00 per Unit. The underwriters did not receive any underwriting discounts or commissions on the Units purchased by Deerfield Management’s affiliate.

Related Party Loans

Our Sponsor loaned us an aggregate of $270,531 to cover expenses related to our Initial Public Offering and working capital needs. The loan was non-interest bearing. We repaid this loan on February 21, 2018.

In addition, in order to finance transaction costs in connection with a Business Combination, our Sponsor or an affiliate of our Sponsor, or certain of our officers and directors may, but are not obligated to, loan us funds as may be required (“Working Capital Loans”). If we complete a Business Combination, we would repay the Working Capital Loans out of the proceeds of the Trust Account released to us. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, we may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity

Table of Contents

at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. To date, we have had no borrowings under the Working Capital Loans.

Services Agreements and Reimbursements

We entered into an agreement, commencing on February 16, 2018 through the earlier of our consummation of a Business Combination and our liquidation, to pay our Sponsor a total of $10,000 per month for office space, utilities and secretarial and administrative support.

We are obligated to pay $7,500 per month to Mr. Wolfe, our Chief Financial Officer, for his services prior to the consummation of the initial Business Combination, subject to the terms of the strategic services agreement.

Our Sponsor, executive officers and directors, or any of their respective affiliates, will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable Business Combinations. Our audit committee will review on a quarterly basis all payments that were made to our Sponsor, officers, directors or their affiliates and will determine which expenses and the amount of expenses that will be reimbursed. There is no cap or ceiling on the reimbursement of out-of-pocket expenses incurred by such persons in connection with activities on our behalf.

We recorded an aggregate of $52,500 during the three months ended September 30, 2019 and 2018 each, and $157,500 and $130,000 during the nine months ended September 30, 2019 and 2018, respectively, in general and administrative expenses in connection with the related agreements in the accompanying unaudited condensed consolidated interim statements of operations.

Critical Accounting Policies and Estimates

This management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to fair value of financial instrument and accrued expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We had identified the following as our critical accounting policies:

Common Stock Subject to Possible Redemption

We account for our common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Shares of common stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable shares of common stock (including shares of common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) are classified as temporary equity. At all other times, shares of common stock are classified as stockholders’ equity. Our common stock features certain redemption rights that are considered to be outside of our control and subject to the occurrence of uncertain future events. Accordingly, at September 30, 2019 and December 31, 2018, 24,055,352 and 24,054,988, respectively, shares of common stock subject to possible redemption at the redemption amount are presented as temporary equity, outside of the stockholders’ equity section of our condensed consolidated balance sheets.

Net Income (Loss) per Share

Net income (loss) per share is computed by dividing net income by the weighted-average number of ordinary shares outstanding during the periods. We have not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of 12,666,666 shares of our common stock in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method.

Our unaudited condensed consolidated interim statements of operations include a presentation of income per share for common stock subject to redemption in a manner similar to the two-class method of income per share. Net income per common share, basic and diluted for public shares is calculated by dividing the interest income earned on the Trust Account, net of applicable taxes and funds available to be withdrawn from the Trust Account for working capital purposes (subject to an annual limit of $250,000), resulting in a total of approximately $1.0 million and $3.3 million for the three and nine months ended September 30, 2019, respectively, by the weighted average number of public shares outstanding for the period. Net loss per common share, basic and diluted for Founder Shares is calculated by dividing the net income, less income attributable to public shares by the weighted average number of Founder Shares outstanding for the period.

Table of Contents

Recent Accounting Pronouncements

Management does not believe that there are any recently issued, but not yet effective, accounting pronouncements, that, if currently adopted, would have a material effect on our unaudited condensed consolidated interim financial statements.

Off-Balance Sheet Arrangements

As of September 30, 2019 and December 31, 2018, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.

Contractual Obligations

We do not have any long-term debt obligations, capital lease obligations, operating lease obligations, purchase obligations or long-term liabilities, other than an agreement to pay our Sponsor a monthly fee of $10,000 for office space, utilities and administrative support and an agreement to pay $7,500 per month to Mr. Wolfe for his services prior to the consummation of the initial Business Combination.

We began incurring these fees on February 16, 2018 and will continue to incur these fees until the earlier of the completion of our initial Business Combination or our liquidation.

JOBS Act

On April 5, 2012, the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) was signed into law. The JOBS Act contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We qualify as an “emerging growth company” and under the JOBS Act are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company”, we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis), and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer’s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our Initial Public Offering or until we are no longer an “emerging growth company,” whichever is earlier.

Proposed Business Combination

On July 8, 2019, we, AdaptHealth Holdings LLC, a Delaware limited liability company (“Adapt”), BM AH Holdings, LLC, a Delaware limited liability company (the “BM Blocker”), Access Point Medical, Inc., a Delaware corporation (the “A Blocker”), DFB Merger Sub LLC, a Delaware limited liability company (“Merger Sub”), AH Representative LLC, a Delaware limited liability company (the “Company Unitholders’ Representative”), and, solely for the limited purposes set forth therein, BlueMountain Foinaven Master Fund L.P., a Cayman Islands exempted limited partnership, BMSB L.P., a Delaware limited partnership, BlueMountain Fursan Fund L.P., a Cayman Islands exempted limited partnership (collectively, the “BM Blocker Sellers”), and Clifton Bay Offshore Investments, L.P., a British Virgin Islands limited partnership (the “A Blocker Seller” and together with the BM Blocker Sellers, the “Blocker Sellers”), entered into an Agreement and Plan of Merger (the “Agreement”) pursuant to which we agreed to combine with Adapt in a transaction (the “Transaction”) that will result in Adapt becoming our partially owned subsidiary. The merger consideration, aggregating $515 million, consists of up to 51.5 million shares of common stock to be issued by us, except that holders of membership interests in Adapt and the Blocker Sellers have the right to receive cash, not to exceed $50.0 million in the aggregate, at the closing of the Transaction, in which case the number of shares to be issued would be reduced by an amount equal to the total amount of cash consideration paid divided by $10.00. Founded in 2012 and headquartered in Plymouth Meeting, PA, Adapt offers a full suite of medical products for both rental and sale, with a focus on respiratory and/or mobility equipment, including CPAP sleep equipment, oxygen equipment, wheelchairs, walkers, and hospital beds. Adapt serves over 1.0 million patients and performs 7,000 deliveries per day across 49 states through more than 150 locations. The consummation of the Transaction is subject to a number of conditions set forth in the Agreement including, among others, receipt of the requisite approval of our stockholders and the execution of the various transaction agreements. It is anticipated that we will change our name to AdaptHealth Corp. upon the consummation of the Transaction.

Table of Contents

On July 8, 2019, the Company entered into a subscription agreement (the “Subscription Agreement”) with Deerfield Private Design Fund IV, L.P. (“Deerfield”), pursuant to which Deerfield agreed to purchase, and the Company agreed to sell to Deerfield, between 5,000,000 and 10,000,000 shares of common stock of the Company (the “PIPE Shares”), depending on the amount of cash available to the Company immediately prior to the consummation of the Transaction, for a purchase price of $10.00 per share, in a private placement. Deerfield also agreed that it would (i) continue to own, through the consummation of the Transaction, the 2.5 million shares of the Company’s common stock it purchased in the Company’s initial public offering; (ii) not exercise its redemption rights with respect to any of such shares; and (iii) vote such shares in favor of the Transaction and any other proposals of the Company set forth in the proxy statement to be filed in connection with the Transaction. The closing of the sale of the PIPE Shares will be contingent upon the substantially concurrent consummation of the Transaction and the satisfaction of other customary closing conditions. The PIPE Shares will be subject to a “lock-up” provision, pursuant to which they may not be sold or otherwise transferred for a period of nine months after the closing date of the Subscription Agreement. Deerfield will have registration rights with respect to the PIPE Shares pursuant to the terms of a registration rights agreement. No fees or other compensation was paid or will be payable to Deerfield or any third parties in consideration of Deerfield entering into the Subscription Agreement. Following the date of the Agreement, subject to the terms and conditions of the Agreement, the Company may enter into additional PIPE subscription agreements.

In connection with the Transaction, the Company, Adapt, and our Sponsor entered into a letter agreement (the “Assignment Letter Agreement”) pursuant to which the Sponsor will, immediately prior to the consummation of the Transaction, transfer and assign to Adapt (or such other equityholder or employee of Adapt as Adapt may designate prior to the consummation of the Transaction), 2,500,000 shares of the Company’s common stock and 1,733,333 warrants to purchase shares of the Company’s common stock (with each warrant exercisable for one-third of a share of the Company’s common stock).

On October 15, 2019, we entered into Amendment No. 1 (the “Amendment”) to the Agreement which, among other things, (i) removes the minimum cash closing condition contained in the Agreement, (ii) adds a new condition to the closing of the Transaction (the “Closing”) with respect to the absence, since the date of the Amendment, of the commencement of an investigation, review or other action concerning a material violation of healthcare law against Adapt by certain regulatory authorities, (iii) adds a provision obligating the Clifton Bay Offshore Investments, L.P. to indemnify the Company against liabilities of the Access Point Medical, Inc., including tax liabilities, arising prior to the Closing and (iv) amend and restate the forms of the amended and restated certificate of incorporation of the Company to be adopted at the Closing and of the tax receivables agreement to be entered into at the Closing.

In connection with the Amendment, on October 15, 2019, the Company, Deerfield and RAB Ventures (DFB) LLC (“RAB Ventures”) entered into an amended and restated subscription agreement (the “A&R Subscription Agreement”), which amends and restates in its entirety the Subscription Agreement, pursuant to which Deerfield had agreed to purchase, and the Company had agreed to sell to Deerfield, between 5,000,000 and 10,000,000 PIPE Shares, depending on the amount of cash available to the Company immediately prior to the Closing (the “Available Cash”), for a purchase price of $10.00 per share, in a private placement. Pursuant to the A&R Subscription Agreement, the number of PIPE Shares to be purchased will be between 5,000,000 and 12,500,000, depending on the amount of Available Cash. If the Available Cash is $75 million or less, then the total number of PIPE Shares to be purchased will equal 12,500,000. If the Available Cash is more than $75 million but less than $100 million, then the total number of PIPE Shares to be purchased will be such number between 10,000,000 and 12,500,000 as is selected by Deerfield in its sole discretion. If the Available Cash is between $100 million and $200 million, then the total number of PIPE Shares to be purchased will equal 10,000,000. If the Available Cash is more than $200 million, then the total number of PIPE Shares to be purchased will be such number of shares of the Company’s common stock (rounded up to the nearest whole number) equal to (A) $300 million minus the amount of Available Cash, divided by (B) ten; provided that in no event will the number of shares purchased be less than 5,000,000. If the total number of PIPE Shares to be purchased is 10,000,000 or less, then Deerfield will purchase all of the PIPE Shares, and if the total number of PIPE Shares to be purchased is more than 10,000,000, then Deerfield will purchase 10,000,000 of the PIPE Shares plus 96% of the PIPE Shares in excess of 10,000,000, and RAB Ventures will purchase the remaining PIPE Shares. RAB Ventures is an entity that is controlled by Richard Barasch, DFB’s President, Chief Executive Officer and Chairman and is one of the members of our Sponsor. Pursuant to the A&R Subscription Agreement, the PIPE Shares will be subject to a “lock-up” provision, pursuant to which they may not be sold or otherwise transferred for a period of time following the Closing. The term of such lock-up period will be nine months for 7,500,000 PIPE Shares purchased by Deerfield, and three months for any other PIPE Shares purchased in excess of that amount by either Deerfield or RAB Ventures. Deerfield (and RAB Ventures, if it purchases any PIPE Shares) will have registration rights with respect to the PIPE Shares pursuant to the terms of a registration rights agreement.

Table of Contents

Agreement. Pursuant to the A&R Assignment Letter Agreement, the Sponsor will, immediately prior to the Closing, transfer and assign to Adapt (or such equityholders or employees of Adapt as Adapt may designate prior to the Closing), for no consideration, between 2,437,500 and 2,500,000 of the shares of the Company’s common stock and between 1,690,000 and 1,733,333 of the warrants to purchase shares of the Company’s common stock held by the Sponsor. The number of shares and warrants to be transferred will be determined based on the number of PIPE Shares purchased pursuant to the A&R Subscription Agreement. If the number of PIPE Shares purchased is 10,000,000 or less, then 2,500,000 shares and 1,733,333 warrants will be transferred. If the number of PIPE Shares purchased is 12,500,000, then 2,437,500 shares and 1,690,000 warrants will be transferred. If the number of PIPE Shares is more than 10,000,000 but less than 12,500,000, then the number of shares and warrants will be calculated on a pro rata basis, based on the number of PIPE Shares purchased in excess of 10,000,000. A portion of the shares to be transferred pursuant to the A&R Assignment Letter Agreement may be transferred by the Company’s executive officers and/or directors instead of the Sponsor.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As of September 30, 2019, we were not subject to any market or interest rate risk. Following the consummation of our Initial Public Offering, the net proceeds of our Initial Public Offering, including amounts in the Trust Account, were invested in U.S. government treasury bills, notes or bonds with a maturity of 180 days or less or in certain money market funds that invest solely in U.S. treasuries. Due to the short-term nature of these investments, we do not believe that there will be an associated material exposure to interest rate risk.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the fiscal quarter ended September 30, 2019. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, during the period covered by this Quarterly Report, our disclosure controls and procedures were effective.

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal quarter ended September 30, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors.

Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in our Annual Report on Form 10-K filed with the SEC on March 29, 2019. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K filed with the SEC on March 29, 2019, except we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

None.

Item 5. Other Information.

None.

Table of Contents

Item 6. Exhibits.

Exhibit Number		Description
2.1		Agreement and Plan of Merger, dated as of July 8, 2019, by and among the Company, Adapt, BM Blocker, A Blocker, Merger Sub, Company Unitholders’ Representative and, solely for purposes of Section 7.20, BM Blocker Sellers, and solely for purposes of Section 7.21, the A Blocker Seller (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K (File No. 001-38399) filed with the SEC on July 12, 2019).

2.2		Amendment No. 1 to the Agreement and Plan of Merger, dated as of October 15, 2019, by and among the Company, Adapt, BM Blocker, A Blocker, Merger Sub, Company Unitholders’ Representative, BM Blocker Sellers, and the A Blocker Seller (incorporated by reference to Exhibit 2.2 to the Company’s Current Report on Form 8-K (File No. 001-38399) filed with the SEC on October 17, 2019).

10.1		Form of Lock-up Agreement, dated as of July 8, 2019, by and among the Company, Adapt and certain members of Adapt (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-38399) filed with the SEC on July 12, 2019).

10.2		Subscription Agreement, dated as of July 8, 2019, by and among the Company and Deerfield (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-38399) filed with the SEC on July 12, 2019).

10.3		Assignment Agreement, dated as of July 8, 2019, by and among the Company, Adapt and the Sponsor (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K (File No. 001-38399) filed with the SEC on July 12, 2019).

10.4		Amended and Restated Subscription Agreement, dated as of October 15, 2019, by and among the Company, Deerfield and RAB Ventures (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-38399) filed with the SEC on October 17, 2019).

10.5		Amended and Restated Assignment Letter Agreement, dated as of October 15, 2019, by and among the Company, Adapt and the Sponsor (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-38399) filed with the SEC on October 17, 2019).

31.1		Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Chief Financial Officer (Principal Financial and Accounting Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of Chief Financial Officer (Principal Financial and Accounting Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

* These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	DFB HEALTHCARE ACQUISITIONS CORP.

Date: November 5, 2019	/s/ Richard Barasch
	Name:	Richard Barasch
	Title:	Chief Executive Officer
		(Principal Executive Officer)

Date: November 5, 2019	/s/ Christopher Wolfe
	Name:	Christopher Wolfe
	Title:	Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-31.1 2 a19-17611_1ex31d1.htm EX-31.1

EXHIBIT 31.1

CERTIFICATION

PURSUANT TO RULE 13a-14 AND 15d-14

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Richard Barasch, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 of DFB Healthcare Acquisitions Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. [Paragraph intentionally omitted in accordance with SEC Release Nos. 34-47986 and 34-54942];

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2019	By:	/s/ Richard Barasch
		Richard Barasch
		Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 a19-17611_1ex31d2.htm EX-31.2

EXHIBIT 31.2

CERTIFICATION

PURSUANT TO RULE 13a-14 AND 15d-14

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Christopher Wolfe, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 of DFB Healthcare Acquisitions Corp.;

b. [Paragraph intentionally omitted in accordance with SEC Release Nos. 34-47986 and 34-54942];

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2019	By:	/s/ Christopher Wolfe
		Christopher Wolfe
		Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1 4 a19-17611_1ex32d1.htm EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. 1350

(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

In connection with the Quarterly Report of DFB Healthcare Acquisitions Corp. (the “Company”) on Form 10-Q for the quarter ended September 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Richard Barasch, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 5, 2019

	/s/ Richard Barasch
	Name:	Richard Barasch
	Title:	Chief Executive Officer
		(Principal Executive Officer)

EX-32.2 5 a19-17611_1ex32d2.htm EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. 1350

(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

In connection with the Quarterly Report of DFB Healthcare Acquisitions Corp. (the “Company”) on Form 10-Q for the quarter ended September 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christopher Wolfe, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 5, 2019

	/s/ Christopher Wolfe
	Name:	Christopher Wolfe
	Title:	Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-101.INS 6 dfbhu-20190930.xml XBRL INSTANCE DOCUMENT 0001725255 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001725255 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001725255 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001725255 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001725255 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001725255 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001725255 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001725255 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001725255 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001725255 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001725255 srt:AffiliatedEntityMember 2018-02-21 2018-02-21 0001725255 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001725255 us-gaap:RetainedEarningsMember 2019-09-30 0001725255 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001725255 us-gaap:RetainedEarningsMember 2019-06-30 0001725255 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001725255 2019-06-30 0001725255 us-gaap:RetainedEarningsMember 2019-03-31 0001725255 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001725255 2019-03-31 0001725255 us-gaap:RetainedEarningsMember 2018-12-31 0001725255 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001725255 us-gaap:RetainedEarningsMember 2018-09-30 0001725255 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001725255 us-gaap:RetainedEarningsMember 2018-06-30 0001725255 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001725255 2018-06-30 0001725255 us-gaap:RetainedEarningsMember 2018-03-31 0001725255 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001725255 2018-03-31 0001725255 us-gaap:RetainedEarningsMember 2017-12-31 0001725255 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001725255 dfbhu:RSubscriptionAgreementMember dfbhu:DeerfieldPrivateDesignFundIvL.p.Member dfbhu:ScenarioFourMember us-gaap:SubsequentEventMember 2019-10-15 0001725255 us-gaap:MajorityShareholderMember dfbhu:PrivatePlacementWarrantsMember 2018-02-21 2018-02-21 0001725255 us-gaap:MajorityShareholderMember 2017-12-15 2017-12-15 0001725255 dfbhu:AdaptHealthHoldingsLLCMember 2019-07-08 0001725255 us-gaap:MajorityShareholderMember 2018-02-21 0001725255 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001725255 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001725255 2019-04-01 2019-06-30 0001725255 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001725255 2019-01-01 2019-03-31 0001725255 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001725255 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001725255 2018-04-01 2018-06-30 0001725255 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001725255 dfbhu:AdministrativeSupportAgreementMember 2019-07-01 2019-09-30 0001725255 dfbhu:AdministrativeSupportAgreementMember 2019-01-01 2019-09-30 0001725255 dfbhu:AdministrativeSupportAgreementMember 2018-07-01 2018-09-30 0001725255 dfbhu:AdministrativeSupportAgreementMember 2018-01-01 2018-09-30 0001725255 us-gaap:CommonStockMember 2019-09-30 0001725255 us-gaap:CommonStockMember 2019-06-30 0001725255 us-gaap:CommonStockMember 2019-03-31 0001725255 us-gaap:CommonStockMember 2018-12-31 0001725255 us-gaap:CommonStockMember 2018-09-30 0001725255 us-gaap:CommonStockMember 2018-06-30 0001725255 us-gaap:CommonStockMember 2018-03-31 0001725255 srt:AffiliatedEntityMember 2018-02-21 0001725255 us-gaap:CommonStockMember 2017-12-31 0001725255 us-gaap:MajorityShareholderMember 2017-12-15 0001725255 dfbhu:RAssignmentLetterAgreementMember dfbhu:AdaptHealthHoldingsLLCMember dfbhu:ScenarioSixMember us-gaap:SubsequentEventMember 2019-10-15 0001725255 dfbhu:RAssignmentLetterAgreementMember dfbhu:AdaptHealthHoldingsLLCMember dfbhu:ScenarioSevenMember us-gaap:SubsequentEventMember 2019-10-15 0001725255 dfbhu:RAssignmentLetterAgreementMember srt:MinimumMember us-gaap:SubsequentEventMember 2019-10-15 0001725255 dfbhu:RAssignmentLetterAgreementMember srt:MaximumMember us-gaap:SubsequentEventMember 2019-10-15 0001725255 dfbhu:AssignmentLetterAgreementMember dfbhu:AdaptHealthHoldingsLLCMember 2019-07-08 0001725255 dfbhu:AssignmentLetterAgreementMember dfbhu:AdaptHealthHoldingsLLCMember 2019-09-30 0001725255 dfbhu:PrivatePlacementWarrantsMember us-gaap:MajorityShareholderMember 2019-09-30 0001725255 2017-12-31 0001725255 dfbhu:AdaptHealthHoldingsLLCMember 2019-01-01 2019-09-30 0001725255 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001725255 2018-01-01 2018-03-31 0001725255 us-gaap:OverAllotmentOptionMember 2018-02-21 2018-02-21 0001725255 dfbhu:LockUpAgreementMember srt:MinimumMember 2019-01-01 2019-09-30 0001725255 dfbhu:LockUpAgreementMember srt:MaximumMember 2019-01-01 2019-09-30 0001725255 dfbhu:RSubscriptionAgreementMember srt:MinimumMember us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:RSubscriptionAgreementMember srt:MaximumMember us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:SubscriptionAgreementMember dfbhu:DeerfieldPrivateDesignFundIvL.p.Member 2019-07-08 2019-07-08 0001725255 dfbhu:LockUpAgreementMember 2019-01-01 2019-09-30 0001725255 dfbhu:RAssignmentLetterAgreementMember srt:MinimumMember dfbhu:AdaptHealthHoldingsLLCMember dfbhu:ScenarioEightMember us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:RAssignmentLetterAgreementMember srt:MinimumMember dfbhu:AdaptHealthHoldingsLLCMember us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:RAssignmentLetterAgreementMember srt:MaximumMember dfbhu:AdaptHealthHoldingsLLCMember us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:RAssignmentLetterAgreementMember dfbhu:AdaptHealthHoldingsLLCMember dfbhu:ScenarioSixMember us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:RAssignmentLetterAgreementMember dfbhu:AdaptHealthHoldingsLLCMember dfbhu:ScenarioSevenMember us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:RSubscriptionAgreementMember dfbhu:DeerfieldPrivateDesignFundIvL.p.Member us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:AssignmentLetterAgreementMember dfbhu:AdaptHealthHoldingsLLCMember 2019-07-08 2019-07-08 0001725255 dfbhu:SubscriptionAgreementMember dfbhu:DeerfieldPrivateDesignFundIvL.p.Member 2019-07-08 0001725255 dfbhu:RSubscriptionAgreementMember srt:MinimumMember dfbhu:DeerfieldPrivateDesignFundIvL.p.Member dfbhu:ScenarioTwoMember us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:RSubscriptionAgreementMember srt:MinimumMember dfbhu:DeerfieldPrivateDesignFundIvL.p.Member dfbhu:ScenarioSixMember us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:RSubscriptionAgreementMember srt:MaximumMember dfbhu:DeerfieldPrivateDesignFundIvL.p.Member dfbhu:ScenarioTwoMember us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:RSubscriptionAgreementMember srt:MaximumMember dfbhu:DeerfieldPrivateDesignFundIvL.p.Member dfbhu:ScenarioSixMember us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:RSubscriptionAgreementMember srt:MinimumMember dfbhu:DeerfieldPrivateDesignFundIvL.p.Member us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:RSubscriptionAgreementMember srt:MaximumMember dfbhu:DeerfieldPrivateDesignFundIvL.p.Member us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:RSubscriptionAgreementMember dfbhu:DeerfieldPrivateDesignFundIvL.p.Member dfbhu:ScenarioThreeMember us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:RSubscriptionAgreementMember dfbhu:DeerfieldPrivateDesignFundIvL.p.Member dfbhu:ScenarioOneMember us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:RSubscriptionAgreementMember dfbhu:DeerfieldPrivateDesignFundIvL.p.Member dfbhu:ScenarioFourMember us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 dfbhu:SubscriptionAgreementMember srt:MinimumMember dfbhu:DeerfieldPrivateDesignFundIvL.p.Member 2019-07-08 2019-07-08 0001725255 dfbhu:SubscriptionAgreementMember srt:MaximumMember dfbhu:DeerfieldPrivateDesignFundIvL.p.Member 2019-07-08 2019-07-08 0001725255 us-gaap:IPOMember 2018-02-21 0001725255 dfbhu:RSubscriptionAgreementMember dfbhu:DeerfieldPrivateDesignFundIvL.p.Member dfbhu:ScenarioFiveMember us-gaap:SubsequentEventMember 2019-10-15 2019-10-15 0001725255 us-gaap:DirectorMember 2017-12-01 2018-01-31 0001725255 us-gaap:ChiefFinancialOfficerMember 2017-12-01 2018-01-31 0001725255 us-gaap:MajorityShareholderMember 2018-04-02 2018-04-02 0001725255 us-gaap:MajorityShareholderMember dfbhu:PrivatePlacementWarrantsMember 2018-02-21 0001725255 dfbhu:PrivatePlacementWarrantsMember us-gaap:MajorityShareholderMember 2018-02-21 0001725255 us-gaap:OverAllotmentOptionMember 2018-02-21 0001725255 dfbhu:PrivatePlacementWarrantsMember us-gaap:MajorityShareholderMember 2018-02-21 2018-02-21 0001725255 us-gaap:MajorityShareholderMember 2018-01-01 2018-09-30 0001725255 us-gaap:MajorityShareholderMember 2019-09-30 0001725255 us-gaap:ChiefFinancialOfficerMember 2019-09-30 0001725255 us-gaap:MajorityShareholderMember 2019-01-01 2019-09-30 0001725255 2019-07-01 2019-09-30 0001725255 2018-07-01 2018-09-30 0001725255 us-gaap:IPOMember 2019-09-30 0001725255 us-gaap:IPOMember 2018-02-21 2018-02-21 0001725255 2018-02-15 0001725255 2018-01-01 2018-09-30 0001725255 2018-09-30 0001725255 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001725255 2019-09-30 0001725255 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001725255 2018-12-31 0001725255 dfbhu:AdaptHealthHoldingsLLCMember 2019-07-08 2019-07-08 0001725255 srt:MaximumMember dfbhu:AdaptHealthHoldingsLLCMember 2019-07-08 2019-07-08 0001725255 2018-02-21 2018-02-21 0001725255 2019-11-05 0001725255 2019-01-01 2019-09-30 dfbhu:item xbrli:pure dfbhu:Vote iso4217:USD xbrli:shares iso4217:USD xbrli:shares false --12-31 Q3 2019 2019-09-30 10-Q 0001725255 31250000 Yes true false Non-accelerated Filer DFB Healthcare Acquisitions Corp. true true 4500000 P20D 250000 250000 250000 250000 50000000 10.00 253019179 253019179 255880268 255880268 622000 622000 876810 3640 P5Y P30D 0.01 P30D 31250000 31250000 238497140 <div> <div>   Common Stock Subject to Possible Redemption   The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Shares of common stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable shares of common stock (including shares of common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, shares of common stock are classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at September 30, 2019 and December 31, 2018, 24,055,352 and 24,054,988, respectively, shares of common stock subject to possible redemption at the redemption amount are presented as temporary equity, outside of the stockholders’ equity section of the Company’s condensed consolidated balance sheets.   <div /></div> </div> 1 190795 7875000 7875000 7875000 7875000 7875000 7875000 0.35 0.07 0.03 0.13 0.04 <div> <div> Emerging Growth Company   Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.   This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. <div /></div> </div> 3300000 1000000 0.200 94 158240 44697 7500 10000 112212 -113543 665756 666000 1448533 1400000 1400000 2726376 4309622 1.50 50000 937500 1500000 150 P150D P30D P1Y 12.00 250000 5000001 3750000 3750000 500000 500000 P10D 1 7000 1000000 937500 100000 30000 P20D 0.33 13060000 13060000 <div> <div>   Offering Costs   Offering costs, which consist of legal, accounting, underwriting fees and other costs that were directly related to the Initial Public Offering, totaled approximately $13.06 million, inclusive of $7.875 million in deferred underwriting commissions. Offering costs were charged to stockholders’ equity upon the completion of the Initial Public Offering.   <div /></div> </div> 0 0.50 0.80 1.00 0.15 96 1.50 250000000 750000 <div> <div> Note 3—Public Offering   On February 21, 2018, the Company sold 25,000,000 Units at a price of $10.00 per Unit in the Initial Public Offering. Each Unit consists of one share of common stock (such shares of common stock included in the Units being offered, the “Public Shares”), and one-third of one redeemable warrant (each, a “Public Warrant”). Each Public Warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment (see Note 6). <div /></div> </div> 10.00 10.00 P30D 18.00 P20D 10.00 10.00 10.00 1.50 1.50 10.00 1.50 147181 53591 149915 50000 10000000 5000000 10000000 300000000 12500000 10000000 12500000 5000000 12500000 12500000 5000000 10000000 2500000 2500000 7500000 2437500 2500000 2500000 2437500 10000000 P9M P9M P9M P3M P6M P3M P24M 900 1300 P45D P45D 0.20 P30D 6250000 6250000 6250000 6250000 25000000 25000000 25000000 25000000 2400000

40774

28675

500379

3125000

2913888

2910249

6500000

12666666

254124282

256626898

1105103

746630

<div> <div> Basis of Presentation   The accompanying unaudited condensed consolidated interim financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ended December 31, 2019, or any future period. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited financial statements contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2019.   <div /></div> </div>

51500000

515000000

119821

846716

947098

622162

726895

-324936

233000

11.50

0.333

1733333

1690000

1733333

0.0001

200000000

7187500

2500000

8319088

7312605

7260773

7195012

7112452

7179201

7194648

7195012

7194648

720

719

4333333

217000

904000

-0.06

-0.02

-0.53

-0.19

0.277

0.980

<div> <div>   The following table presents information about the Company’s assets that are measured on a recurring basis as of September 30, 2019 and December 31, 2018 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value.   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2019 </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:15.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant Other </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant Other </td> </tr> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> in Active Markets </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable Inputs </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable Inputs </td> </tr> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash and marketable securities held in Trust Account </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 255,880,268 </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2018 </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:15.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant Other </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant Other </td> </tr> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> in Active Markets </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable Inputs </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable Inputs </td> </tr> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash and marketable securities held in Trust Account </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 253,019,179 </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Note 7—Fair Value Measurements   The following table presents information about the Company’s assets that are measured on a recurring basis as of September 30, 2019 and December 31, 2018 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value.   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2019 </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:15.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant Other </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant Other </td> </tr> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> in Active Markets </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable Inputs </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable Inputs </td> </tr> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash and marketable securities held in Trust Account </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 255,880,268 </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2018 </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:15.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant Other </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant Other </td> </tr> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> in Active Markets </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable Inputs </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable Inputs </td> </tr> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash and marketable securities held in Trust Account </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 253,019,179 </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> </table></div>   Approximately $1,300 and $900 of the balance in the Trust Account was held in cash as of September 30, 2019 and December 31, 2018, respectively. <div /></div> </div>

<div> <div> Financial Instruments   The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented on the condensed consolidated balance sheets. <div /></div> </div>

604502

130000

391160

52500

3285654

157500

1195246

52500

1974693

760077

877992

122188

630000

934925

546213

241760

874355

276661

<div> <div>   Income Taxes   The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of September 30, 2019 and December 31, 2018, the Company has a deferred tax asset of approximately $904,000 and $217,000 respectively, which has a full valuation allowance recorded against it.   The Company’s current taxable income primarily consists of interest income on the Trust Account. The Company’s general and administrative costs are generally considered start-up costs and are not currently deductible. During the three and nine months ended September 30, 2019 and 2018, the Company recorded income tax expense of approximately $277,000 and $874,000 in 2019, and approximately $242,000 and $546,000 in 2018, respectively, primarily related to interest income earned on the Trust Account. The Company’s effective tax rate for the nine months ended September 30, 2019 and 2018 was approximately 98.0% and 27.7%, respectively, which differs from the expected income tax rate due to the start-up costs (discussed above) which are not currently deductible.   FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2019 and December 31, 2018. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.   <div /></div> </div>

-46400

-12099

202217

2624621

240037

-33537

5900000

2726376

1204828

4313561

1367434

8574393

11073372

254124282

256626898

699393

3198372

251331043

-249334244

1448533

-1269904

-1773469

220333

1428480

689830

518317

825598

3637

-667488

-154473

270531

-751683

-444751

-3435569

-1245246

<div> <div> Note 1—Description of Organization and Business Operations   DFB Healthcare Acquisitions Corp. (the “Company”) was incorporated in Delaware on November 22, 2017. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). Although the Company is not limited to a particular industry or sector for purposes of consummating a Business Combination, the Company intends to focus its search on the healthcare or healthcare related industries. The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.   As of September 30, 2019, the Company had not commenced any operations. All activity for the period from November 22, 2017 (inception) through September 30, 2019 relates to the Company’s formation, the Company’s initial public offering (the “Initial Public Offering”), and, since the closing of the Initial Public Offering, the search for a prospective initial Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering.   The Company’s sponsor is Deerfield/RAB Ventures, LLC, a Delaware limited liability company (the “Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on February 15, 2018.  On February 21, 2018, the Company consummated its Initial Public Offering of 25,000,000 units (each, a “Unit” and collectively, the “Units”) sold to the public at the price of $10.00 per Unit, generating gross proceeds of $250 million and incurring offering costs of approximately $13.06 million, inclusive of $7.875 million in deferred underwriting commissions (Note 5). The underwriter was granted a 45-day option from the date of the final prospectus relating to the Initial Public Offering to purchase up to 3,750,000 additional Units to cover over-allotments, if any, at $10.00 per Unit. The over-allotment option was not exercised prior to its expiration on April 2, 2018.   Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (the “Private Placement”) of 4,333,333 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant to the Sponsor, generating gross proceeds of $6.5 million (Note 4).  The Sponsor had agreed that, had the over-allotment option been exercised, the Sponsor would have purchased up to an additional 500,000 Private Placement Warrants at a price of $1.50 per Private Placement Warrant.   Upon the closing of the Initial Public Offering and the Private Placement, $250 million ($10.00 per Unit) of the net proceeds of the sale of the Units in the Initial Public Offering and the Private Placement was placed in a trust account (the “Trust Account”), located in the United States at J.P. Morgan Chase Bank, N.A., with Continental Stock Transfer & Trust Company acting as trustee, and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of paragraphs (d)(2), (d)(3) and (d)(4) of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below.   At September 30, 2019, the Company had approximately $622,000 in cash held outside of the Trust Account. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.   The Company will provide its holders of the outstanding shares of its common stock, par value $0.0001, sold in the Initial Public Offering (the “public stockholders”) with the opportunity to redeem all or a portion of their Public Shares (as defined below in Note 3) upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially at $10.00 per Public Share). The per-share amount to be distributed to public stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5). These Public Shares are recorded at a redemption value and classified as temporary equity in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company decides not to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transactions is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the initial stockholders (as defined below) agreed to vote their Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. The Company’s insiders must: (i) refrain from purchasing shares during certain blackout periods and when they are in possession of any material non-public information and (ii) to clear all trades with the Company’s legal counsel prior to execution. In addition, the initial stockholders agreed to waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of a Business Combination.   Notwithstanding the foregoing, the Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the common stock sold in the Initial Public Offering, without the prior consent of the Company.   The Company’s Sponsor, officers and directors (the “initial stockholders”) agreed not to propose an amendment to the Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the public stockholders with the opportunity to redeem their shares of common stock in conjunction with any such amendment.   If the Company is unable to complete a Business Combination within 24 months from the closing of the Initial Public Offering, or February 21, 2020 (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest (less up to $50,000 of interest to pay dissolution expenses, which interest shall be net of taxes payable by the Company and any amounts released to the Company to fund working capital requirements, subject to an annual limit of $250,000), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.   The initial stockholders agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the initial stockholders should acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to their deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be less than the $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a definitive agreement for a Business Combination, reduce the amount of funds in the Trust Account to below (i) $10.00 per Public Share or (ii) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company has sought and will continue to seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.   On July 8, 2019, the Company, AdaptHealth Holdings LLC, a Delaware limited liability company (“Adapt”), BM AH Holdings, LLC, a Delaware limited liability company, Access Point Medical, Inc., a Delaware corporation, DFB Merger Sub LLC, a Delaware limited liability company, AH Representative LLC, a Delaware limited liability company, and, solely for the limited purposes set forth therein, BlueMountain Foinaven Master Fund L.P., a Cayman Islands exempted limited partnership, BMSB L.P., a Delaware limited partnership, BlueMountain Fursan Fund L.P., a Cayman Islands exempted limited partnership, and Clifton Bay Offshore Investments, L.P., a British Virgin Islands limited partnership (collectively, the “Blocker Sellers”), entered into an Agreement and Plan of Merger (the “Agreement”), which was later amended on October 15, 2019, pursuant to which the Company agreed to combine with Adapt in a transaction (the “Transaction”) that will result in Adapt becoming a partially owned subsidiary of the Company. It is anticipated that the Company will change its name to AdaptHealth Corp. upon the consummation of the Transaction (Note 8).   Liquidity and Going Concern   In connection with the Company’s assessment of going concern considerations in accordance with FASB’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” the Company’s management has determined that the mandatory liquidation and subsequent dissolution raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after February 21, 2020.   Through September 30, 2019, the Company's liquidity needs have been satisfied through receipt of a $25,000 capital contribution from the Sponsor in exchange for the issuance of the Founder Shares (Note 4) to the Sponsor, $270,531 in loans from the Sponsor (which was fully repaid on February 21, 2018), the proceeds from the consummation of the Private Placement not held in the Trust Account, and interest withdrawn from the Trust Account for working capital and tax purposes. The Company withdrew approximately $1.4 million and $666,000 of interest income from the Trust Account during the nine months ended September 30, 2019 and 2018, respectively to pay for tax obligations and working capital purposes. Of the $1.4 million of interest income withdrawn in 2019, $250,000 was for working capital.   As of September 30, 2019, the Company had approximately $622,000 in its operating bank account, and approximately $5.9 million of interest income available to fund a Business Combination (which interest shall be net of taxes payable by the Company and any amounts, subject to an annual limit of $250,000, released to the Company to fund working capital requirements), and a working capital deficit of approximately $2.4 million. In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”) (see Note 4). The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. Based on the foregoing, the Company may have insufficient funds available to operate its business through February 21, 2020. Following the initial Business Combination, if cash on hand is insufficient, the Company may need to obtain additional financing in order to meet its obligations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. The Company's plans to raise capital or to consummate the initial Business Combination may not be successful. These matters, among others, raise substantial doubt about the Company's ability to continue as a going concern. <div /></div> </div>

4994717

0.0001

1000000

158005

124468

250000000

25000

6500000

96291

270531

2085401

2089038

10.00

<div> <div> Note 2—Summary of Significant Accounting Policies   Basis of Presentation   The accompanying unaudited condensed consolidated interim financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ended December 31, 2019, or any future period. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited financial statements contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2019.   Principles of Consolidation   The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, DFB Merger Sub LLC, a Delaware limited liability company, formed on June 17, 2019. All significant intercompany balances and transactions have been eliminated in consolidation.   Emerging Growth Company   Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.   This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.   Concentration of Credit Risk   Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. At September 30, 2019 and December 31, 2018, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.   Cash and Cash Equivalents   The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had approximately $233,000 and $0 in cash equivalents as of September 30, 2019 and December 31, 2018, respectively.   Financial Instruments   The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented on the condensed consolidated balance sheets.   Use of Estimates   The preparation of the financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.   Offering Costs   Offering costs, which consist of legal, accounting, underwriting fees and other costs that were directly related to the Initial Public Offering, totaled approximately $13.06 million, inclusive of $7.875 million in deferred underwriting commissions. Offering costs were charged to stockholders’ equity upon the completion of the Initial Public Offering.   Common Stock Subject to Possible Redemption   The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Shares of common stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable shares of common stock (including shares of common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, shares of common stock are classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at September 30, 2019 and December 31, 2018, 24,055,352 and 24,054,988, respectively, shares of common stock subject to possible redemption at the redemption amount are presented as temporary equity, outside of the stockholders’ equity section of the Company’s condensed consolidated balance sheets.   Net Income (Loss) per Share   Net income (loss) per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the periods. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of 12,666,666 shares of the Company’s common stock in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method.   The Company’s unaudited condensed consolidated interim statements of operations include a presentation of income per share for common stock subject to redemption in a manner similar to the two-class method of income per share. Net income per common share, basic and diluted for Public Shares is calculated by dividing the interest income earned on the Trust Account, net of applicable taxes and funds available to be withdrawn from the Trust Account for working capital purposes (subject to an annual limit of $250,000), resulting in a total of approximately $1.0 million and $3.3 million for the three and nine months ended September 30, 2019, respectively, by the weighted average number of Public Shares outstanding for the periods. Net loss per common share, basic and diluted for Founder Shares is calculated by dividing the net income, less income attributable to Public Shares by the weighted average number of Founder Shares outstanding for the periods.   Income Taxes   The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of September 30, 2019 and December 31, 2018, the Company has a deferred tax asset of approximately $904,000 and $217,000 respectively, which has a full valuation allowance recorded against it.   The Company’s current taxable income primarily consists of interest income on the Trust Account. The Company’s general and administrative costs are generally considered start-up costs and are not currently deductible. During the three and nine months ended September 30, 2019 and 2018, the Company recorded income tax expense of approximately $277,000 and $874,000 in 2019, and approximately $242,000 and $546,000 in 2018, respectively, primarily related to interest income earned on the Trust Account. The Company’s effective tax rate for the nine months ended September 30, 2019 and 2018 was approximately 98.0% and 27.7%, respectively, which differs from the expected income tax rate due to the start-up costs (discussed above) which are not currently deductible.   FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2019 and December 31, 2018. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.   Recent Accounting Pronouncements   The Company’s management does not believe that there are any recently issued, but not yet effective, accounting pronouncements, that, if currently adopted, would have a material effect on the Company’s unaudited condensed consolidated interim financial statements.   <div /></div> </div>

24307

24281

719

-693

5000008

4779536

832

219640

5000008

4089807

731

909470

5000005

3571492

726

1427787

5000009

2913888

720

2085401

5000007

2088297

711

2910999

5000009

2755780

718

2243511

5000006

2910249

719

2089038

25000000

10.00

937500

236939488

236936988

2500

25000000

4333333

-94

23868412

68983

51832

82560

-66749

-15447

238684120

238681733

2387

689830

689823

518320

518315

825600

825591

-667490

-667483

-7

-154470

-154469

-1

240549880

240553520

0.0001

24054988

24055352

EX-101.SCH 7 dfbhu-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Description of Organization and Business Operations (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Public Offering (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Related Party Transactions - Services Agreements and Reimbursements (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Commitments & Contingencies - Underwriting Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Merger Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Description of Organization and Business Operations link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Public Offering link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Commitments & Contingencies link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Merger Agreement link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 dfbhu-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.LAB 9 dfbhu-20190930_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Document and Entity Information Statement [Table] Statement [Line Items] Statement Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus CONDENSED CONSOLIDATED BALANCE SHEETS Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents - end of the period Cash and cash equivalents - beginning of the period Cash and cash equivalents Prepaid Expense, Current Prepaid expenses Assets, Current Total current assets Amount of currency on hand as well as demand deposits with banks or financial institutions held in trust account classified as non-current. Cash and Cash Equivalents, Held in Trust Account Cash and marketable securities held in Trust Account Cash and marketable securities held in Trust Account Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Carrying value as of the balance sheet date of obligations incurred and payable for franchise taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Franchise Taxes Payable, Current Franchise tax payable Liabilities, Current Total current liabilities The noncurrent portion of deferred underwriting commission as of balance sheet date. Deferred Underwriting Commissions, Noncurrent Deferred underwriting commissions Liabilities Total liabilities Commitments and Contingencies Commitments and Contingencies Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests Common stock, $0.0001 par value; 24,055,352 and 24,054,988 shares subject to possible redemption at September 30, 2019 and December 31, 2018, respectively Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Equity: Preferred Stock, Value, Issued Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding Common Stock, Value, Issued Common stock, $0.0001 par value; 200,000,000 shares authorized; 7,194,648 and 7,195,012 shares issued and outstanding (excluding 24,055,352 and 24,054,988 shares subject to possible redemption) at September 30, 2019 and December 31, 2018, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Retained earnings Stockholders' Equity Attributable to Parent Balance Balance Total stockholders' equity Liabilities and Equity Total Liabilities and Stockholders' Equity Temporary Equity, Par or Stated Value Per Share Temporary stock, par value (in dollars per share) Temporary Equity, Shares Outstanding Temporary stock, shares outstanding (in shares) Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized (in shares) Preferred Stock, Shares Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Outstanding Preferred stock, shares outstanding (in shares) Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized (in shares) Common Stock, Shares, Issued Balance (in shares) Balance (in shares) Common stock, shares issued (in shares) Shares issued (in shares) Common Stock, Shares, Outstanding Common stock, shares outstanding (in shares) UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS General and Administrative Expense General and administrative expenses The amount payable for state franchise taxes. State Franchise Taxes State franchise taxes Operating Income (Loss) Loss from operations Investment Income, Interest Interest income Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income before income tax expense Income Tax Expense (Benefit) Income tax expense Net Income (Loss) Attributable to Parent Net income Net (loss) income Net income (loss) Average number of shares or units issued and outstanding on public shares that are used in calculating basic and diluted earnings per share (EPS). Weighted Average Number of Shares Outstanding on Public Shares, Basic and Diluted Basic and diluted weighted average Public Shares (Note 3) outstanding The amount of net income or loss for the period per each public share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Earnings Per Public Share, Basic and Diluted Basic and diluted net income per Public Share Average number of shares or units issued and outstanding on founder shares that are used in calculating basic and diluted earnings per share (EPS). Weighted Average Number of Shares Outstanding on Founder Shares, Basic and Diluted Basic and diluted weighted average Founder Shares (Note 4) outstanding Earnings Per Share, Basic and Diluted Basic and diluted net loss per Founder Share UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Stock Issued During Period, Value, New Issues Sale of units in initial public offering, net of offering costs Units issued (in units) Stock Issued During Period, Shares, New Issues Sale of units in initial public offering, net of offering costs (in shares) Price per unit Adjustments to Additional Paid in Capital, Warrant Issued Sale of private placement warrants to Sponsor in private placement Stock Issued During Period, Value, Share-based Compensation, Forfeited Founder shares forfeited Stock Issued During Period, Shares, Share-based Compensation, Forfeited Founder shares forfeited (in shares) Stock Redeemed or Called During Period, Value Common stock subject to possible redemption Stock Redeemed or Called During Period, Shares Common stock subject to possible redemption (in shares) UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flows from Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash used in operating activities: Amount before accretion (amortization) of purchase discount (premium) of interest held in trust account. Investment Income, Interest Held In Trust Account Interest income in cash and marketable securities held in Trust Account Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense Prepaid expenses Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses The increase (decrease) during the reporting period of Franchise taxes owed but not paid. Increase (Decrease) in Franchise Taxes Franchise tax payable Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flows from Investing Activities: The cash outflow associated with principal deposited in trust account. Principal Deposited in Trust Account Principal deposited in Trust Account The cash inflow associated with Interest released from trust account. Interest Released From Trust Account Interest released from Trust Account Interest withdrawn from Trust Account Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows from Financing Activities: Proceeds from Notes Payable Proceeds from notes payable to related parties Repayments of Notes Payable Repayment of notes payable to related parties Proceeds from Issuance Initial Public Offering Proceeds received from initial public offering Payments of Stock Issuance Costs Payment of offering costs Proceeds from Issuance of Warrants Proceeds received from private placement Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net change in cash and cash equivalents Noncash Investing and Financing Items [Abstract] Supplemental disclosure of noncash investing and financing activities: The amount of deferred underwriting commissions in connection with the initial public offering in noncash investing or financing activities. Deferred Underwriting Commissions Deferred underwriting commissions charged to equity in connection with the initial public offering Deferred offering costs charged to equity in noncash investing or financing activities. Deferred Offering Costs Charged to Equity Deferred offering costs charged to equity upon completion of the initial public offering The amount of common stock subject to possible redemption in noncash investing or financing activities. Common Stock, Subject to Possible Redemption Value of common stock subject to possible redemption The amount of change in common stock value subject to possible redemption in noncash investing or financing activities. Change in Common Stock, Value, Subject to Possible Redemption Change in value of common stock subject to possible redemption Amount of founder shares forfeited. Founder Shares Forfeited Founder shares forfeited Supplemental Cash Flow Information [Abstract] Supplemental disclosures of cash flow information: Income Taxes Paid Cash paid for income taxes Description of Organization and Business Operations Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Description of Organization and Business Operations Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies No definition available. Public Offering The disclosure of information about public offering. Public Offering [Text Block] Public Offering Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions Commitments & Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments & Contingencies Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Merger Agreement Business Combination Disclosure [Text Block] Merger Agreement Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Consolidation, Policy [Policy Text Block] Principles of consolidation Disclosure of accounting policy for emerging growth company. Emerging Growth Company [Policy Text Block] Emerging Growth Company Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Fair Value of Financial Instruments, Policy [Policy Text Block] Financial Instruments Use of Estimates, Policy [Policy Text Block] Use of Estimates Disclosure of accounting policy for offering cost. Offering Costs [Policy Text Block] Offering Costs Disclosure of accounting policy for common stock subject to redemption. Common Stock Subject to Redemption [Policy Text Block] Common Stock Subject to Possible Redemption Earnings Per Share, Policy [Policy Text Block] Net Income (Loss) per Share Income Tax, Policy [Policy Text Block] Income Taxes New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of financial assets measured at fair value Schedule of Capital Units [Table] Public ofering Description of Organization and Business Operations Significant Accounting Policies The term of underwriting agreement , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Underwriters Option Term Underwriting option term Per unit amount received for each capital unit issued or sold in the stock transaction. Sale Of Stock Price Per Unit Offer price (in dollars per unit) Debt Conversion, Converted Instrument, Warrants or Options Issued Warrants issued (in warrants) Amount of offering costs incurred for Initial Public Offering. Offering Costs Initial Public Offering Offering costs Number of additional units to be purchased to cover over-allotment. Number of Additional Units to be Purchased to Cover Over-allotment Number of additional units to be purchased to cover over-allotment Number of additional warrants to be purchased by Sponsor upon exercise of over-allotment. Number of Additional Warrants to be Purchased upon Exercise of Over-allotment Additional warrants available (in warrants) Percentage of aggregate fair value of assets held in Trust Account to complete initial business combinations. Percentage of Aggregate Fair Value of Assets Held in Trust Account to Complete Initial Business Combinations Aggregate fair value of assets held in Trust Account (as a percent) Percentage of acquisition of outstanding voting securities post initial business combination transaction of the target company. Percentage of Acquisition of Outstanding Voting Securities Acquisition of outstanding voting securities (as a percent) Amount of net tangible assets of target company as a condition for proceeding with business combinations. Net Tangible Assets of Target Company for Proceeding with Business Combination Net tangible assets Percentage of restriction on redemption of common stock sold as per the Amended and Restated Certificate of Incorporation. Percentage of Restriction on Redemption of Common Stock Sold Restriction on redemption of common stock sold (as a percent) Percentage of redemption obligation of shares upon non completion of business combination. Percentage of Redemption Obligation of Shares upon Non Completion of Business Combination Redemption obligation of shares upon non completion of business combination (as a percent) Term to complete business combination from closing of Initial Public Offering. Term to Complete Business Combination from Closing of Proposed Public Offering Term to complete business combination Number of business days for redemption of shares. Number of Business Days for Redemption of Shares Number of business days to redeem public shares Amount of maximum reduction in interest to pay dissolution expenses. Maximum Reduction in Interest for Payment of Dissolution Expenses Maximum reduction in interest to pay dissolution expenses Amount of annual ceiling of amount released to the Company for funding working capital requirements. Annual ceiling limit Annual limit of amount released to the Company to fund working capital requirements Amount to be paid per public share by entity upon redemption. Public Shares, Redemption Price Per Share Redemption price (in dollars per share) Amount of current assets less current liabilities. Net Current Assets Working Capital Amount of cash held by the entity outside of the Trust Account. Cash Held Outside of Trust Account Interest Receivable Interest available Proceeds from Issuance of Common Stock Proceeds from issuance of common stock to Sponsor Notes Payable, Related Parties, Noncurrent Loan from related party Represents the working capital deficit of the entity. Working Capital Deficit Working capital deficit Cash Equivalents, at Carrying Value Cash equivalents Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of warrants excluded in the calculation of diluted income per share Total amount of estimated annual ceiling of amount released to the Company for funding working capital requirements. Estimated Total Annual Ceiling limit Estimated total annual ceiling limit Deferred Income Tax Assets, Net Deferred tax asset Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Unrecognized Tax Benefits Unrecognized tax benefits Number of common shares comprised in each unit. Number of Common Shares Comprised in Each Unit Shares in single unit (in shares) Number of warrants comprised in each unit. Number of Warrants Comprised in Each Unit Number of warrants comprised in each unit Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Common stock exercisable for each warrant Number of shares for each warrant Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Statement line items Related Party Transactions The number of shares transferred by sponsor to initial stockholders. Number of Shares Transferred by Sponsor to Initial Stockholders Founder shares transferred The maximum number of shares included in common stock subject to forfeiture. Maximum Shares Subject to Forfeiture Shares subject to forfeiture Issued price per warrant. Price Per Warrant The forfeiture will be adjusted to the extent that the over-allotment option is not exercised in full by the underwriters. So the percentage of issued and outstanding shares adjusted after initial public offer. Forfeiture Adjusted Percentage to Issued and Outstanding Shares Forfeiture adjusted percentage to issued and outstanding shares Number of shares forfeited due to over allotment option expired. Number of Shares Forfeited Number of shares forfeited Minimum period for not to transfer, assign or sell of any shares agreed by initial stockholders. Minimum Period for Not to Transfer, Assign or Sell of any Founder Shares Minimum period for not to transfer, assign or sell of any shares Minimum price for not to transfer, assign or sell of any founder shares agreed by initial stockholders. Minimum Price for Not to Transfer, Assign or Sell of any Founder Shares Minimum price for not to transfer, assign or sell of any founder shares Number of trading days considered in a period of 30 trading days for minimum price evaluation. Number of Trading Days Considered in a Period of 30 Trading Days for Minimum Price Evaluation Number of trading days considered in a period of 30 trading days for minimum price alternative Minimum period considering price per share alternative from the date of initial business combination. Minimum Period for Considering Price Per Share Alternative Minimum period for considering price per share alternative Issued price of additional warrants. Issued Price of Additional Warrants Proceeds to be received upon exercise of additional warrants. Proceeds to be Received Upon Additional Warrants Exercised Proceeds to be received upon additional warrants exercised The amount of maximum working capital loans may be converted to warrants. Maximum Working Capital Loans may be Converted to Warrants Maximum working capital loans may be converted to warrants The amount of borrowings outstanding under working capital loans. Outstanding Borrowings Under Working Capital Loans Outstanding borrowings under working capital loans The amount of general and administration expenses payable per month as per agreement. General and Administrative Expense Payable Per Month Monthly payment amount Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Underwriting Agreement The per unit amount of underwriting discount paid. Underwriting Discount Paid Underwriting discount paid (per Unit) The cash outflow associated with payment of underwriters discount. Aggregate Underwriting Discount Paid Underwriters discount paid The per unit deferred underwriting commissions payable. Deferred Underwriting Commissions Payable Deferred underwriting commissions (per Unit) Number of votes per common share. Common Stock, Voting Rights per Each Share Number of votes per common stock Number of shares of common stock outstanding including shares subject to possible redemption. Common stock represent the ownership interest in a corporation. Common Stock, Shares, Outstanding, Including Shares Subject to Possible Redemption Common stock, shares outstanding including shares subject to possible redemption (in shares) Number of days after completion of business combination warrants or rights exercisable, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Class of Warrant or Right, Number of Days after Completion of Business Combination Warrants or Rights Exercisable Exercisable period after the completion of a Business Combination Agreed duration to file registration statement with SEC after business combination, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Agreed Duration to file Registration Statement with SEC after Business Combination Agreed duration to file registration with SEC Warrants expiration period after business combination, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Class of Warrant or Right, Expiration Period After Business Combination Warrant expiration period Warrants lock in period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Warrants Lock in Period Warrant non transferable period Redemption price of warrant. Class of Warrant or Right, Redemption Price Redemption price of warrant EX-101.PRE 10 dfbhu-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 11 dfbhu-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT XML 12 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)		3 Months Ended		9 Months Ended
	Feb. 21, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Significant Accounting Policies
Annual ceiling limit				$ 250,000
Cash equivalents		$ 233,000		$ 233,000		$ 0
Deferred underwriting commissions charged to equity in connection with the initial public offering					$ 7,875,000
Temporary stock, shares outstanding (in shares)		24,055,352		24,055,352		24,054,988
Number of warrants excluded in the calculation of diluted income per share				12,666,666
Estimated total annual ceiling limit		$ 1,000,000		$ 3,300,000
Deferred tax asset		904,000		904,000		$ 217,000
Income Tax Expense (Benefit)		276,661	$ 241,760	$ 874,355	$ 546,213
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent				98.00%	27.70%
Unrecognized tax benefits		$ 0		$ 0		$ 0
IPO
Significant Accounting Policies
Offering costs	$ 13,060,000
Deferred underwriting commissions charged to equity in connection with the initial public offering	$ 7,875,000

XML 13 R14.htm IDEA: XBRL DOCUMENT

Merger Agreement	9 Months Ended
Merger Agreement	Sep. 30, 2019
Merger Agreement
Merger Agreement	Note 8—Merger Agreement On July 8, 2019, the Company, Adapt, BM AH Holdings, LLC, a Delaware limited liability company, Access Point Medical, Inc., a Delaware corporation, DFB Merger Sub LLC, a Delaware limited liability company, AH Representative LLC, a Delaware limited liability company, and, solely for the limited purposes set forth therein, BlueMountain Foinaven Master Fund L.P., a Cayman Islands exempted limited partnership, BMSB L.P., a Delaware limited partnership, BlueMountain Fursan Fund L.P., a Cayman Islands exempted limited partnership, and Clifton Bay Offshore Investments, L.P., a British Virgin Islands limited partnership, entered into the Agreement pursuant to which the Company agreed to combine with Adapt in a transaction that will result in Adapt becoming the Company’s partially owned subsidiary. The merger consideration, aggregating $515 million, consists of up to 51.5 million shares of common stock to be issued by the Company, except that holders of membership interests in Adapt and the Blocker Sellers have the right to receive cash, not to exceed $50.0 million in the aggregate, at the closing of the Transaction, in which case the number of shares to be issued would be reduced by an amount equal to the total amount of cash consideration paid divided by $10.00. Founded in 2012 and headquartered in Plymouth Meeting, PA, Adapt offers a full suite of medical products for both rental and sale, with a focus on respiratory and/or mobility equipment, including CPAP sleep equipment, oxygen equipment, wheelchairs, walkers, and hospital beds. Adapt serves over 1.0 million patients and performs 7,000 deliveries per day across 49 states through more than 150 locations. The consummation of the Transaction is subject to a number of conditions set forth in the Agreement including, among others, receipt of the requisite approval of the Company’s stockholders and the execution of the various transaction agreements. It is anticipated that the Company will change its name to AdaptHealth Corp. upon the consummation of the Transaction. In connection with the execution of the Agreement, the Company, Adapt and certain members of Adapt, entered into a lock-up agreement (the “Lock-up Agreement”). Under the terms of the Lock-up Agreement, such members agreed to certain lock-up arrangements with the Company, pursuant to which: (i) certain of such members will be restricted from selling, transferring or pledging any securities of the Company they receive in connection with the Transaction for a period of nine months from the closing of the Transaction and (ii) certain members of Adapt are restricted from selling, transferring or pledging such securities for a period of either six months or three months from the closing of the Transaction, depending upon whether such member has made a liquidity request as contemplated by Section 7.19 of the Agreement. On July 8, 2019, the Company entered into a subscription agreement (the “Subscription Agreement”) with Deerfield Private Design Fund IV, L.P. (“Deerfield”), pursuant to which Deerfield agreed to purchase, and the Company agreed to sell to Deerfield, between 5,000,000 and 10,000,000 shares of common stock of the Company (the “PIPE Shares”), depending on the amount of cash available to the Company immediately prior to the consummation of the Transaction, for a purchase price of $10.00 per share, in a private placement. Deerfield also agreed that it would (i) continue to own, through the consummation of the Transaction, the 2.5 million shares of the Company’s common stock it purchased in the Company’s initial public offering; (ii) not exercise its redemption rights with respect to any of such shares; and (iii) vote such shares in favor of the Transaction and any other proposals of the Company set forth in the proxy statement to be filed by the Company in connection with the Transaction. The closing of the sale of the PIPE Shares will be contingent upon the substantially concurrent consummation of the Transaction and the satisfaction of other customary closing conditions. The PIPE Shares will be subject to a “lock-up” provision, pursuant to which they may not be sold or otherwise transferred for a period of nine months after the closing date of the Subscription Agreement. Deerfield will have registration rights with respect to the PIPE Shares pursuant to the terms of a registration rights agreement. No fees or other compensation was paid or will be payable to Deerfield or any third parties in consideration of Deerfield entering into the Subscription Agreement. Following the date of the Agreement, subject to the terms and conditions of the Agreement, the Company may enter into additional PIPE subscription agreements. In connection with the Transaction, the Company, Adapt, and the Sponsor entered into a letter agreement (the “Assignment Letter Agreement”) pursuant to which the Sponsor will, immediately prior to the consummation of the Transaction, transfer and assign to Adapt (or such other equityholder or employee of Adapt as Adapt may designate prior to the consummation of the Transaction), 2,500,000 shares of the Company’s common stock and 1,733,333 warrants to purchase shares of the Company’s common stock (with each warrant exercisable for one-third of a share of the Company’s common stock). On October 15, 2019, the Company entered into Amendment No. 1 (the “Amendment”) to the Agreement which, among other things, (i) removes the minimum cash closing condition contained in the Agreement, (ii) adds a new condition to the closing of the Transaction (the “Closing”) with respect to the absence, since the date of the Amendment, of the commencement of an investigation, review or other action concerning a material violation of healthcare law against Adapt by certain regulatory authorities, (iii) adds a provision obligating the Clifton Bay Offshore Investments, L.P. to indemnify the Company against liabilities of the Access Point Medical, Inc., including tax liabilities, arising prior to the Closing and (iv) amend and restate the forms of the amended and restated certificate of incorporation of the Company to be adopted at the Closing and of the tax receivables agreement to be entered into at the Closing. In connection with the Amendment, on October 15, 2019, the Company, Deerfield and RAB Ventures (DFB) LLC (“RAB Ventures”) entered into an amended and restated subscription agreement (the “A&R Subscription Agreement”), which amends and restates in its entirety the Subscription Agreement, pursuant to which Deerfield had agreed to purchase, and the Company had agreed to sell to Deerfield, between 5,000,000 and 10,000,000 PIPE Shares, depending on the amount of cash available to the Company immediately prior to the Closing (the “Available Cash”), for a purchase price of $10.00 per share, in a private placement. Pursuant to the A&R Subscription Agreement, the number of PIPE Shares to be purchased will be between 5,000,000 and 12,500,000, depending on the amount of Available Cash. If the Available Cash is $75 million or less, then the total number of PIPE Shares to be purchased will equal 12,500,000. If the Available Cash is more than $75 million but less than $100 million, then the total number of PIPE Shares to be purchased will be such number between 10,000,000 and 12,500,000 as is selected by Deerfield in its sole discretion. If the Available Cash is between $100 million and $200 million, then the total number of PIPE Shares to be purchased will equal 10,000,000. If the Available Cash is more than $200 million, then the total number of PIPE Shares to be purchased will be such number of shares of the Company’s common stock (rounded up to the nearest whole number) equal to (A) $300 million minus the amount of Available Cash, divided by (B) ten; provided that in no event will the number of shares purchased be less than 5,000,000. If the total number of PIPE Shares to be purchased is 10,000,000 or less, then Deerfield will purchase all of the PIPE Shares, and if the total number of PIPE Shares to be purchased is more than 10,000,000, then Deerfield will purchase 10,000,000 of the PIPE Shares plus 96% of the PIPE Shares in excess of 10,000,000, and RAB Ventures will purchase the remaining PIPE Shares. RAB Ventures is an entity that is controlled by Richard Barasch, the Company’s President, Chief Executive Officer and Chairman and is one of the members of the Sponsor. Pursuant to the A&R Subscription Agreement, the PIPE Shares will be subject to a “lock-up” provision, pursuant to which they may not be sold or otherwise transferred for a period of time following the Closing. The term of such lock-up period will be nine months for 7,500,000 PIPE Shares purchased by Deerfield, and three months for any other PIPE Shares purchased in excess of that amount by either Deerfield or RAB Ventures. Deerfield (and RAB Ventures, if it purchases any PIPE Shares) will have registration rights with respect to the PIPE Shares pursuant to the terms of a registration rights agreement. In connection with the Amendment, on October 15, 2019, the Company, Adapt and the Sponsor entered into an amended and restated letter agreement (the “A&R Assignment Letter Agreement”), which amends and restates in its entirety the Assignment Letter Agreement. Pursuant to the A&R Assignment Letter Agreement, the Sponsor will, immediately prior to the Closing, transfer and assign to Adapt (or such equityholders or employees of Adapt as Adapt may designate prior to the Closing), for no consideration, between 2,437,500 and 2,500,000 of the shares of the Company’s common stock and between 1,690,000 and 1,733,333 of the warrants to purchase shares of the Company’s common stock held by the Sponsor. The number of shares and warrants to be transferred will be determined based on the number of PIPE Shares purchased pursuant to the A&R Subscription Agreement. If the number of PIPE Shares purchased is 10,000,000 or less, then 2,500,000 shares and 1,733,333 warrants will be transferred. If the number of PIPE Shares purchased is 12,500,000, then 2,437,500 shares and 1,690,000 warrants will be transferred. If the number of PIPE Shares is more than 10,000,000 but less than 12,500,000, then the number of shares and warrants will be calculated on a pro rata basis, based on the number of PIPE Shares purchased in excess of 10,000,000. A portion of the shares to be transferred pursuant to the A&R Assignment Letter Agreement may be transferred by the Company’s executive officers and/or directors instead of the Sponsor. In connection with the proposed Transaction, the Company filed a preliminary proxy statement with the SEC relating to the Transaction on August 19, 2019. the Company subsequently filed Amendment No. 1 and Amendment No. 2 to the preliminary proxy statement with the SEC on September 24, 2019 and Amendment No. 3 to the preliminary proxy statement on October 15, 2019. The Company filed the definitive proxy statement with the SEC relating to the Transaction on October 23, 2019 and mailed it to the Company’s stockholders on October 25, 2019.

XML 14 R10.htm IDEA: XBRL DOCUMENT

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2019
Related Party Transactions
Related Party Transactions	Note 4—Related Party Transactions Founder Shares On December 15, 2017, the Sponsor purchased 7,187,500 shares (the “Founder Shares”) of the Company’s common stock, par value $0.0001 for an aggregate price of $25,000. In December 2017 and January 2018, the Sponsor transferred 100,000 Founder Shares to Christopher Wolfe, the Company’s Chief Financial Officer, and 30,000 Founder Shares to each of Steven Hochberg, Dr. Susan Weaver, Dr. Mohit Kaushal and Dr. Gregory Sorensen, the Company’s independent directors. The initial stockholders agreed to forfeit up to 937,500 Founder Shares to the extent that the over‑allotment option was not exercised in full by the underwriters. The forfeiture was to be adjusted to the extent that the over-allotment option was not exercised in full by the underwriters so that the Founder Shares would represent 20.0% of the Company’s issued and outstanding shares after the Initial Public Offering. On April 2, 2018, the over-allotment option expired and an aggregate of 937,500 shares were subsequently forfeited by the initial stockholders. The initial stockholders agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the last sale price of the common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Company’s stockholders having the right to exchange their shares of common stock for cash, securities or other property. Private Placement Warrants Concurrently with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 4,333,333 Private Placement Warrants at a price of $1.50 per Private Placement Warrant, generating gross proceeds of $6.5 million in the Private Placement. The Sponsor had agreed that if the over-allotment option was exercised, the Sponsor would have purchased up to an additional 500,000 Private Placement Warrants at a price of $1.50 per Private Placement Warrant, for additional gross proceeds of $750,000. Each Private Placement Warrant is exercisable for one share of common stock at a price of $11.50 per share. The proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees. The Sponsor and the Company’s officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Warrants until 30 days after the completion of the initial Business Combination. An affiliate of Deerfield Management Company, L.P, a Delaware series limited partnership (“Deerfield Management”), which is a significant owner of the Sponsor, purchased 2,500,000 Units in the Initial Public Offering at $10.00 per Unit. The underwriters did not receive any underwriting discounts or commissions on the Units purchased by Deerfield Management’s affiliate. Related Party Loans The Sponsor loaned the Company an aggregate of $270,531 to cover expenses related to the Initial Public Offering and working capital needs. The loan was non-interest bearing. The Company repaid this loan on February 21, 2018. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company Working Capital Loans. If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. To date, the Company had no borrowings under the Working Capital Loans. Services Agreements and Reimbursements The Company entered into an agreement, commencing on February 16, 2018 through the earlier of the Company’s consummation of a Business Combination and its liquidation, to pay the Sponsor a total of $10,000 per month for office space, utilities and secretarial and administrative support. The Company is obligated to pay $7,500 per month to Mr. Wolfe, the Company’s Chief Financial Officer, for his services prior to the consummation of the initial Business Combination, subject to the terms of the strategic services agreement. The Sponsor, executive officers and directors, or any of their respective affiliates, will be reimbursed for any out-of-pocket expenses incurred in connection with activities on the Company’s behalf such as identifying potential target businesses and performing due diligence on suitable Business Combinations. The Company’s audit committee will review on a quarterly basis all payments that were made to the Sponsor, officers, directors or their affiliates and will determine which expenses and the amount of expenses that will be reimbursed. There is no cap or ceiling on the reimbursement of out-of-pocket expenses incurred by such persons in connection with activities on the Company’s behalf. The Company recorded an aggregate of $52,500 during the three months ended September 30, 2019 and 2018 each, and $157,500 and $130,000 during the nine months ended September 30, 2019 and 2018, respectively, in general and administrative expenses in connection with the related agreements in the accompanying unaudited condensed consolidated interim statements of operations.

XML 15 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2019
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 2—Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated interim financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ended December 31, 2019, or any future period. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited financial statements contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2019. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, DFB Merger Sub LLC, a Delaware limited liability company, formed on June 17, 2019. All significant intercompany balances and transactions have been eliminated in consolidation. Emerging Growth Company Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. At September 30, 2019 and December 31, 2018, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had approximately $233,000 and $0 in cash equivalents as of September 30, 2019 and December 31, 2018, respectively. Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented on the condensed consolidated balance sheets. Use of Estimates The preparation of the financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. Offering Costs Offering costs, which consist of legal, accounting, underwriting fees and other costs that were directly related to the Initial Public Offering, totaled approximately $13.06 million, inclusive of $7.875 million in deferred underwriting commissions. Offering costs were charged to stockholders’ equity upon the completion of the Initial Public Offering. Common Stock Subject to Possible Redemption The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Shares of common stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable shares of common stock (including shares of common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, shares of common stock are classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at September 30, 2019 and December 31, 2018, 24,055,352 and 24,054,988, respectively, shares of common stock subject to possible redemption at the redemption amount are presented as temporary equity, outside of the stockholders’ equity section of the Company’s condensed consolidated balance sheets. Net Income (Loss) per Share Net income (loss) per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the periods. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of 12,666,666 shares of the Company’s common stock in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method. The Company’s unaudited condensed consolidated interim statements of operations include a presentation of income per share for common stock subject to redemption in a manner similar to the two-class method of income per share. Net income per common share, basic and diluted for Public Shares is calculated by dividing the interest income earned on the Trust Account, net of applicable taxes and funds available to be withdrawn from the Trust Account for working capital purposes (subject to an annual limit of $250,000), resulting in a total of approximately $1.0 million and $3.3 million for the three and nine months ended September 30, 2019, respectively, by the weighted average number of Public Shares outstanding for the periods. Net loss per common share, basic and diluted for Founder Shares is calculated by dividing the net income, less income attributable to Public Shares by the weighted average number of Founder Shares outstanding for the periods. Income Taxes The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of September 30, 2019 and December 31, 2018, the Company has a deferred tax asset of approximately $904,000 and $217,000 respectively, which has a full valuation allowance recorded against it. The Company’s current taxable income primarily consists of interest income on the Trust Account. The Company’s general and administrative costs are generally considered start-up costs and are not currently deductible. During the three and nine months ended September 30, 2019 and 2018, the Company recorded income tax expense of approximately $277,000 and $874,000 in 2019, and approximately $242,000 and $546,000 in 2018, respectively, primarily related to interest income earned on the Trust Account. The Company’s effective tax rate for the nine months ended September 30, 2019 and 2018 was approximately 98.0% and 27.7%, respectively, which differs from the expected income tax rate due to the start-up costs (discussed above) which are not currently deductible. FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2019 and December 31, 2018. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. Recent Accounting Pronouncements The Company’s management does not believe that there are any recently issued, but not yet effective, accounting pronouncements, that, if currently adopted, would have a material effect on the Company’s unaudited condensed consolidated interim financial statements.

XML 16 R4.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS
General and administrative expenses	$ 1,195,246	$ 391,160	$ 3,285,654	$ 604,502
State franchise taxes	50,000	53,591	149,915	147,181
Loss from operations	(1,245,246)	(444,751)	(3,435,569)	(751,683)
Interest income	1,367,434	1,204,828	4,313,561	2,726,376
Income before income tax expense	122,188	760,077	877,992	1,974,693
Income tax expense	276,661	241,760	874,355	546,213
Net (loss) income	$ (154,473)	$ 518,317	$ 3,637	$ 1,428,480
Basic and diluted weighted average Public Shares (Note 3) outstanding	25,000,000	25,000,000	25,000,000	25,000,000
Basic and diluted net income per Public Share	$ 0.04	$ 0.03	$ 0.13	$ 0.07
Basic and diluted weighted average Founder Shares (Note 4) outstanding	6,250,000	6,250,000	6,250,000	6,250,000
Basic and diluted net loss per Founder Share	$ (0.19)	$ (0.02)	$ (0.53)	$ (0.06)

XML 17 R22.htm IDEA: XBRL DOCUMENT

Commitments & Contingencies - Underwriting Agreement (Details) - USD ($)		9 Months Ended
	Feb. 21, 2018	Sep. 30, 2019	Dec. 31, 2018
Underwriting Agreement
Underwriting discount paid (per Unit)	$ 0.20
Underwriters discount paid	$ 4,500,000
Deferred underwriting commissions (per Unit)		$ 0.35
Deferred underwriting commissions		$ 7,875,000	$ 7,875,000
Shares issued (in shares)		7,194,648	7,195,012
Over-Allotment Option
Underwriting Agreement
Underwriting option term	45 days
Number of additional units to be purchased to cover over-allotment	3,750,000
IPO
Underwriting Agreement
Deferred underwriting commissions		$ 7,875,000
Deerfield Management
Underwriting Agreement
Shares issued (in shares)	2,500,000

EXCEL 18 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 19 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 20 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 126 250 1 false 32 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.dfbhealthcareacquisitionscorp.com/role/StatementCondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.dfbhealthcareacquisitionscorp.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS Sheet http://www.dfbhealthcareacquisitionscorp.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfOperations UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00300 - Statement - UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://www.dfbhealthcareacquisitionscorp.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInStockholdersEquity UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 00400 - Statement - UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS Sheet http://www.dfbhealthcareacquisitionscorp.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 10101 - Disclosure - Description of Organization and Business Operations Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations Description of Organization and Business Operations Notes 7 false false R8.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 10301 - Disclosure - Public Offering Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosurePublicOffering Public Offering Notes 9 false false R10.htm 10401 - Disclosure - Related Party Transactions Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 10 false false R11.htm 10501 - Disclosure - Commitments & Contingencies Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureCommitmentsContingencies Commitments & Contingencies Notes 11 false false R12.htm 10601 - Disclosure - Stockholders' Equity Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 12 false false R13.htm 10701 - Disclosure - Fair Value Measurements Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 10801 - Disclosure - Merger Agreement Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureMergerAgreement Merger Agreement Notes 14 false false R15.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureSummaryOfSignificantAccountingPolicies 15 false false R16.htm 30703 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureFairValueMeasurements 16 false false R17.htm 40101 - Disclosure - Description of Organization and Business Operations (Details) Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails Description of Organization and Business Operations (Details) Details http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations 17 false false R18.htm 40201 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies 18 false false R19.htm 40301 - Disclosure - Public Offering (Details) Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosurePublicOfferingDetails Public Offering (Details) Details http://www.dfbhealthcareacquisitionscorp.com/role/DisclosurePublicOffering 19 false false R20.htm 40401 - Disclosure - Related Party Transactions (Details) Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureRelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureRelatedPartyTransactions 20 false false R21.htm 40402 - Disclosure - Related Party Transactions - Services Agreements and Reimbursements (Details) Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureRelatedPartyTransactionsServicesAgreementsAndReimbursementsDetails Related Party Transactions - Services Agreements and Reimbursements (Details) Details 21 false false R22.htm 40501 - Disclosure - Commitments & Contingencies - Underwriting Agreement (Details) Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureCommitmentsContingenciesUnderwritingAgreementDetails Commitments & Contingencies - Underwriting Agreement (Details) Details 22 false false R23.htm 40601 - Disclosure - Stockholders' Equity (Details) Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureStockholdersEquityDetails Stockholders' Equity (Details) Details http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureStockholdersEquity 23 false false R24.htm 40701 - Disclosure - Fair Value Measurements (Details) Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureFairValueMeasurementsTables 24 false false R25.htm 40801 - Disclosure - Merger Agreement (Details) Sheet http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureMergerAgreementDetails Merger Agreement (Details) Details http://www.dfbhealthcareacquisitionscorp.com/role/DisclosureMergerAgreement 25 false false All Reports Book All Reports dfbhu-20190930.xml dfbhu-20190930.xsd dfbhu-20190930_cal.xml dfbhu-20190930_def.xml dfbhu-20190930_lab.xml dfbhu-20190930_pre.xml http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true XML 21 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 22 R23.htm IDEA: XBRL DOCUMENT v3.19.3

Stockholders' Equity (Details)
9 Months Ended

Sep. 30, 2019

$ / shares

shares

Dec. 31, 2018

$ / shares

shares

Feb. 15, 2018

Vote

$ / shares

shares

Stockholders' Equity

Common stock, shares authorized (in shares) 200,000,000 200,000,000 200,000,000

Common stock, par value (in dollars per share) | $ / shares $ 0.0001 $ 0.0001 $ 0.0001

Number of votes per common stock | Vote 1

Common stock, shares outstanding including shares subject to possible redemption (in shares) 31,250,000 31,250,000

Temporary stock, shares outstanding (in shares) 24,055,352 24,054,988

Preferred stock, shares authorized (in shares) 1,000,000 1,000,000

Preferred stock, par value (in dollars per share) | $ / shares $ 0.0001 $ 0.0001

Preferred stock, shares issued (in shares) 0 0

Preferred stock, shares outstanding (in shares) 0 0

Exercisable period after the completion of a Business Combination 30 days

Agreed duration to file registration with SEC 20 days

Warrant expiration period 5 years

Warrant non transferable period 30 days

Redemption price of warrant | $ / shares $ 0.01

Prior notice period 30 days

Minimum closing price of ordinary share | $ / shares $ 18.00

Number of trading days price must be equal or above target price 20 days

Total number of trading days 30 days

X

- Definition
Agreed duration to file registration statement with SEC after business combination, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: dfbhu_AgreedDurationToFileRegistrationStatementWithSecAfterBusinessCombination

Namespace Prefix: dfbhu_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants expiration period after business combination, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: dfbhu_ClassOfWarrantOrRightExpirationPeriodAfterBusinessCombination

Namespace Prefix: dfbhu_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of days after completion of business combination warrants or rights exercisable, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: dfbhu_ClassOfWarrantOrRightNumberOfDaysAfterCompletionOfBusinessCombinationWarrantsOrRightsExercisable

Namespace Prefix: dfbhu_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Redemption price of warrant.
+ References
No definition available.
+ Details

Name: dfbhu_ClassOfWarrantOrRightRedemptionPrice

Namespace Prefix: dfbhu_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Term of prior notice for warrants redemption, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: dfbhu_ClassOfWarrantOrRightTermOfPriorNotice

Namespace Prefix: dfbhu_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of common stock outstanding including shares subject to possible redemption. Common stock represent the ownership interest in a corporation.
+ References
No definition available.
+ Details

Name: dfbhu_CommonStockSharesOutstandingIncludingSharesSubjectToPossibleRedemption

Namespace Prefix: dfbhu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of votes per common share.
+ References
No definition available.
+ Details

Name: dfbhu_CommonStockVotingRightsPerEachShare

Namespace Prefix: dfbhu_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Redemption of warrant obligation period of trading days ending on third trading day prior to the date of sending notice, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: dfbhu_RedemptionOfWarrantObligationPeriodOfTradingDaysEndingOnThirdTradingDayPriorToDateOfSendingNotice

Namespace Prefix: dfbhu_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Redemption of warrant trading price of ordinary share test number of trading days price must remain equal or above calculated target, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: dfbhu_RedemptionOfWarrantTradingPriceOfOrdinaryShareTestNumberOfTradingDaysPriceMustRemainAboveCalculatedTarget

Namespace Prefix: dfbhu_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Minimum closing price of ordinary share.
+ References
No definition available.
+ Details

Name: dfbhu_RedemptionOfWarrantsClosingTradingPriceOrdinaryStockUsedAsTarget

Namespace Prefix: dfbhu_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants lock in period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: dfbhu_WarrantsLockInPeriod

Namespace Prefix: dfbhu_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 23 R15.htm IDEA: XBRL DOCUMENT v3.19.3

Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2019

Summary of Significant Accounting Policies

Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed consolidated interim financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ended December 31, 2019, or any future period. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited financial statements contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2019.

Principles of consolidation

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, DFB Merger Sub LLC, a Delaware limited liability company, formed on June 17, 2019. All significant intercompany balances and transactions have been eliminated in consolidation.

Emerging Growth Company

Emerging Growth Company

Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.

This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. At September 30, 2019 and December 31, 2018, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had approximately $233,000 and $0 in cash equivalents as of September 30, 2019 and December 31, 2018, respectively.

Financial Instruments

Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented on the condensed consolidated balance sheets.

Use of Estimates

Use of Estimates

The preparation of the financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.

Offering Costs

Offering Costs

Offering costs, which consist of legal, accounting, underwriting fees and other costs that were directly related to the Initial Public Offering, totaled approximately $13.06 million, inclusive of $7.875 million in deferred underwriting commissions. Offering costs were charged to stockholders’ equity upon the completion of the Initial Public Offering.

Common Stock Subject to Possible Redemption

Common Stock Subject to Possible Redemption

The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Shares of common stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable shares of common stock (including shares of common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, shares of common stock are classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at September 30, 2019 and December 31, 2018, 24,055,352 and 24,054,988, respectively, shares of common stock subject to possible redemption at the redemption amount are presented as temporary equity, outside of the stockholders’ equity section of the Company’s condensed consolidated balance sheets.

Net Income (Loss) per Share

Net Income (Loss) per Share

Net income (loss) per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the periods. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of 12,666,666 shares of the Company’s common stock in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method.

The Company’s unaudited condensed consolidated interim statements of operations include a presentation of income per share for common stock subject to redemption in a manner similar to the two-class method of income per share. Net income per common share, basic and diluted for Public Shares is calculated by dividing the interest income earned on the Trust Account, net of applicable taxes and funds available to be withdrawn from the Trust Account for working capital purposes (subject to an annual limit of $250,000), resulting in a total of approximately $1.0 million and $3.3 million for the three and nine months ended September 30, 2019, respectively, by the weighted average number of Public Shares outstanding for the periods. Net loss per common share, basic and diluted for Founder Shares is calculated by dividing the net income, less income attributable to Public Shares by the weighted average number of Founder Shares outstanding for the periods.

Income Taxes

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of September 30, 2019 and December 31, 2018, the Company has a deferred tax asset of approximately $904,000 and $217,000 respectively, which has a full valuation allowance recorded against it.

The Company’s current taxable income primarily consists of interest income on the Trust Account. The Company’s general and administrative costs are generally considered start-up costs and are not currently deductible. During the three and nine months ended September 30, 2019 and 2018, the Company recorded income tax expense of approximately $277,000 and $874,000 in 2019, and approximately $242,000 and $546,000 in 2018, respectively, primarily related to interest income earned on the Trust Account. The Company’s effective tax rate for the nine months ended September 30, 2019 and 2018 was approximately 98.0% and 27.7%, respectively, which differs from the expected income tax rate due to the start-up costs (discussed above) which are not currently deductible.

FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2019 and December 31, 2018. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

The Company’s management does not believe that there are any recently issued, but not yet effective, accounting pronouncements, that, if currently adopted, would have a material effect on the Company’s unaudited condensed consolidated interim financial statements.

X

- Definition
Disclosure of accounting policy for common stock subject to redemption.
+ References
No definition available.
+ Details

Name: dfbhu_CommonStockSubjectToRedemptionPolicyTextBlock

Namespace Prefix: dfbhu_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for emerging growth company.
+ References
No definition available.
+ Details

Name: dfbhu_EmergingGrowthCompanyPolicyTextBlock

Namespace Prefix: dfbhu_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for offering cost.
+ References
No definition available.
+ Details

Name: dfbhu_OfferingCostsPolicyTextBlock

Namespace Prefix: dfbhu_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.3A-03)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 60
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13279-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R11.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments & Contingencies
9 Months Ended

Sep. 30, 2019

Commitments & Contingencies

Commitments & Contingencies

Note 5—Commitments & Contingencies

Registration Rights

The holders of Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans, if any, and any shares of common stock underlying such securities, will be entitled to registration rights pursuant to a registration rights agreement entered into on February 15, 2018. These holders will be entitled to certain demand and “piggyback” registration rights. However, the registration rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until the termination of the applicable lock-up period for the securities to be registered. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The Company granted the underwriters a 45-day option from the date of the final prospectus relating to the Initial Public Offering to purchase up to 3,750,000 additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. The option expired on April 2, 2018.

The underwriters were entitled to an underwriting discount of $0.20 per Unit, or $4.5 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per Unit, or $7.875 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

The underwriters did not receive any underwriting discounts or commissions on the 2,500,000 Units purchased by Deerfield Management in the Initial Public Offering.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R19.htm IDEA: XBRL DOCUMENT v3.19.3

Public Offering (Details) - USD ($)
3 Months Ended

Feb. 21, 2018

Mar. 31, 2018

Sep. 30, 2019

Description of Organization and Business Operations

Units issued (in units) $ 236,939,488

Offer price (in dollars per unit) $ 10.00

IPO

Description of Organization and Business Operations

Units issued (in units) $ 25,000,000

Price per unit 10.00

Offer price (in dollars per unit) $ 10.00

Shares in single unit (in shares) 1

Number of warrants comprised in each unit 0.33

Common stock exercisable for each warrant 1

Exercise price of warrants $ 11.50

X

- Definition
Number of common shares comprised in each unit.
+ References
No definition available.
+ Details

Name: dfbhu_NumberOfCommonSharesComprisedInEachUnit

Namespace Prefix: dfbhu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of warrants comprised in each unit.
+ References
No definition available.
+ Details

Name: dfbhu_NumberOfWarrantsComprisedInEachUnit

Namespace Prefix: dfbhu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per unit amount received for each capital unit issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: dfbhu_SaleOfStockPricePerUnit

Namespace Prefix: dfbhu_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_CapitalUnitLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 R5.htm IDEA: XBRL DOCUMENT v3.19.3

UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)

Common Stock

Additional Paid-in Capital

Retained Earnings (Accumulated Deficit)

Total

Balance at Dec. 31, 2017 $ 719 $ 24,281 $ (693) $ 24,307

Balance (in shares) at Dec. 31, 2017 7,187,500

Sale of units in initial public offering, net of offering costs $ 2,500 236,936,988 236,939,488

Sale of units in initial public offering, net of offering costs (in shares) 25,000,000

Sale of private placement warrants to Sponsor in private placement 6,500,000 6,500,000

Common stock subject to possible redemption $ (2,387) (238,681,733) (238,684,120)

Common stock subject to possible redemption (in shares) (23,868,412)

Net income (loss) 220,333 220,333

Balance at Mar. 31, 2018 $ 832 4,779,536 219,640 5,000,008

Balance (in shares) at Mar. 31, 2018 8,319,088

Balance at Dec. 31, 2017 $ 719 24,281 (693) 24,307

Balance (in shares) at Dec. 31, 2017 7,187,500

Net income (loss) 1,428,480

Balance at Sep. 30, 2018 $ 726 3,571,492 1,427,787 5,000,005

Balance (in shares) at Sep. 30, 2018 7,260,773

Balance at Mar. 31, 2018 $ 832 4,779,536 219,640 5,000,008

Balance (in shares) at Mar. 31, 2018 8,319,088

Founder shares forfeited $ (94) 94

Founder shares forfeited (in shares) (937,500)

Common stock subject to possible redemption $ (7) (689,823) (689,830)

Common stock subject to possible redemption (in shares) (68,983)

Net income (loss) 689,830 689,830

Balance at Jun. 30, 2018 $ 731 4,089,807 909,470 5,000,008

Balance (in shares) at Jun. 30, 2018 7,312,605

Common stock subject to possible redemption $ (5) (518,315) (518,320)

Common stock subject to possible redemption (in shares) (51,832)

Net income (loss) 518,317 518,317

Balance at Sep. 30, 2018 $ 726 3,571,492 1,427,787 5,000,005

Balance (in shares) at Sep. 30, 2018 7,260,773

Balance at Dec. 31, 2018 $ 720 2,913,888 2,085,401 $ 5,000,009

Balance (in shares) at Dec. 31, 2018 7,195,012 7,195,012

Common stock subject to possible redemption $ (9) (825,591) $ (825,600)

Common stock subject to possible redemption (in shares) (82,560)

Net income (loss) 825,598 825,598

Balance at Mar. 31, 2019 $ 711 2,088,297 2,910,999 5,000,007

Balance (in shares) at Mar. 31, 2019 7,112,452

Balance at Dec. 31, 2018 $ 720 2,913,888 2,085,401 $ 5,000,009

Balance (in shares) at Dec. 31, 2018 7,195,012 7,195,012

Net income (loss) $ 3,637

Balance at Sep. 30, 2019 $ 719 2,910,249 2,089,038 $ 5,000,006

Balance (in shares) at Sep. 30, 2019 7,194,648 7,194,648

Balance at Mar. 31, 2019 $ 711 2,088,297 2,910,999 $ 5,000,007

Balance (in shares) at Mar. 31, 2019 7,112,452

Common stock subject to possible redemption $ 7 667,483 667,490

Common stock subject to possible redemption (in shares) 66,749

Net income (loss) (667,488) (667,488)

Balance at Jun. 30, 2019 $ 718 2,755,780 2,243,511 5,000,009

Balance (in shares) at Jun. 30, 2019 7,179,201

Common stock subject to possible redemption $ 1 154,469 154,470

Common stock subject to possible redemption (in shares) 15,447

Net income (loss) (154,473) (154,473)

Balance at Sep. 30, 2019 $ 719 $ 2,910,249 $ 2,089,038 $ 5,000,006

Balance (in shares) at Sep. 30, 2019 7,194,648 7,194,648

X

- Definition
Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares (or other type of equity) forfeited during the period.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of forfeitures of stock or other type of equity issued of any equity-based compensation plan other than an employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph c(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of stock bought back by the entity at the exercise price or redemption price.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockRedeemedOrCalledDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockRedeemedOrCalledDuringPeriodValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 27 R1.htm IDEA: XBRL DOCUMENT v3.19.3

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2019

Nov. 05, 2019

Document and Entity Information

Entity Registrant Name DFB Healthcare Acquisitions Corp.

Entity Central Index Key 0001725255

Document Type 10-Q

Document Period End Date Sep. 30, 2019

Amendment Flag false

Current Fiscal Year End Date --12-31

Entity Current Reporting Status Yes

Entity Filer Category Non-accelerated Filer

Entity Small Business true

Entity Emerging Growth Company true

Entity Ex Transition Period false

Entity Shell Company true

Entity Common Stock, Shares Outstanding 31,250,000

Document Fiscal Year Focus 2019

Document Fiscal Period Focus Q3

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: dfbhu_DocumentAndEntityInformationAbstract

Namespace Prefix: dfbhu_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R9.htm IDEA: XBRL DOCUMENT v3.19.3

Public Offering
9 Months Ended

Sep. 30, 2019

Public Offering

Public Offering

Note 3—Public Offering

On February 21, 2018, the Company sold 25,000,000 Units at a price of $10.00 per Unit in the Initial Public Offering. Each Unit consists of one share of common stock (such shares of common stock included in the Units being offered, the “Public Shares”), and one-third of one redeemable warrant (each, a “Public Warrant”). Each Public Warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment (see Note 6).

X

- References
No definition available.
+ Details

Name: dfbhu_PublicOfferingAbstract

Namespace Prefix: dfbhu_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The disclosure of information about public offering.
+ References
No definition available.
+ Details

Name: dfbhu_PublicOfferingTextBlock

Namespace Prefix: dfbhu_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 29 0001104659-19-060125-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-19-060125-xbrl.zip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end XML 30 R25.htm IDEA: XBRL DOCUMENT v3.19.3

Merger Agreement (Details)
$ / shares in Units, $ in Millions
9 Months Ended

Oct. 15, 2019

$ / shares

shares

Jul. 08, 2019

USD ($)

item

$ / shares

shares

Sep. 30, 2019

USD ($)

shares

Lock-up Agreement

Business Acquisition

Term for restriction from selling, transferring or pledging any securities of the Company 9 months

Adapt

Business Acquisition

Total Merger Consideration | $ $ 515.0

Cash Consideration Dividing Factor (in dollars per share) | $ / shares $ 10.00

Number Of Deliveries Per Day | item 7,000

States of Operation 49

Number of Locations 150

Adapt | Assignment Letter Agreement

Business Acquisition

Shares of the Company's common stock issued 2,500,000

Warrants to purchase shares of common stock 1,733,333

Number of shares for each warrant 0.333

Adapt | Subsequent Event | Shares purchased is 10,000,000 or less | A&R Assignment Letter Agreement

Business Acquisition

Shares of the Company's common stock issued 2,500,000

Warrants to purchase shares of common stock 1,733,333

Adapt | Subsequent Event | Shares purchased is 12,500,000 | A&R Assignment Letter Agreement

Business Acquisition

Shares of the Company's common stock issued 2,437,500

Warrants to purchase shares of common stock 1,690,000

Deerfield | Subscription Agreement

Business Acquisition

Term for restriction from selling, transferring or pledging any securities of the Company 9 months

Purchase price | $ / shares $ 10.00

Number of shares owed by acquirer 2,500,000

Deerfield | Subsequent Event | A&R Subscription Agreement

Business Acquisition

Shares of the Company's common stock issued 7,500,000

Deerfield | Subsequent Event | Available Cash is $75 million or less | A&R Subscription Agreement

Business Acquisition

Number of common stock agreed to issued 12,500,000

Deerfield | Subsequent Event | Available Cash is between $100 million and $200 million | A&R Subscription Agreement

Business Acquisition

Number of common stock agreed to issued 10,000,000

Deerfield | Subsequent Event | Available Cash is more than $200 million | A&R Subscription Agreement

Business Acquisition

Number of common stock agreed to issued 300,000,000

Purchase price | $ / shares $ 10

Deerfield | Subsequent Event | Total number of Shares to be purchased is more than 10,000,000 | A&R Subscription Agreement

Business Acquisition

Number of common stock agreed to issued 10,000,000

Percentage of shares to be purchased in excess of 10000000 96

Minimum | Lock-up Agreement

Business Acquisition

Term for restriction from selling, transferring or pledging any securities of the Company for certain members of adapt 3 months

Minimum | Subsequent Event | A&R Subscription Agreement

Business Acquisition

Term for restriction from selling, transferring or pledging any securities of the Company 3 months

Minimum | Subsequent Event | A&R Assignment Letter Agreement

Business Acquisition

Warrants to purchase shares of common stock 1,690,000

Minimum | Adapt | Subsequent Event | A&R Assignment Letter Agreement

Business Acquisition

Shares of the Company's common stock issued 2,437,500

Minimum | Adapt | Subsequent Event | Shares purchased is more than 10,000,000 but less than 12,500,000 | A&R Assignment Letter Agreement

Business Acquisition

Shares of the Company's common stock issued 10,000,000

Minimum | Deerfield | Subscription Agreement

Business Acquisition

Number of common stock agreed to issued 5,000,000

Minimum | Deerfield | Subsequent Event | A&R Subscription Agreement

Business Acquisition

Number of common stock agreed to issued 5,000,000

Minimum | Deerfield | Subsequent Event | Available Cash is more than $75 million but less than $100 million | A&R Subscription Agreement

Business Acquisition

Number of common stock agreed to issued 10,000,000

Minimum | Deerfield | Subsequent Event | Shares purchased is 10,000,000 or less | A&R Subscription Agreement

Business Acquisition

Number of common stock agreed to issued 5,000,000

Maximum | Lock-up Agreement

Business Acquisition

Term for restriction from selling, transferring or pledging any securities of the Company for certain members of adapt 6 months

Maximum | Subsequent Event | A&R Subscription Agreement

Business Acquisition

Term for restriction from selling, transferring or pledging any securities of the Company 9 months

Maximum | Subsequent Event | A&R Assignment Letter Agreement

Business Acquisition

Warrants to purchase shares of common stock 1,733,333

Maximum | Adapt

Business Acquisition

Common Stock issued as per Merger Agreement (in shares) 51,500,000

Maximum Cash Consideration | $ $ 50.0

Number of Patients | $ $ 1.0

Maximum | Adapt | Subsequent Event | A&R Assignment Letter Agreement

Business Acquisition

Shares of the Company's common stock issued 2,500,000

Maximum | Deerfield | Subscription Agreement

Business Acquisition

Number of common stock agreed to issued 10,000,000

Maximum | Deerfield | Subsequent Event | A&R Subscription Agreement

Business Acquisition

Number of common stock agreed to issued 12,500,000

Maximum | Deerfield | Subsequent Event | Available Cash is more than $75 million but less than $100 million | A&R Subscription Agreement

Business Acquisition

Number of common stock agreed to issued 12,500,000

Maximum | Deerfield | Subsequent Event | Shares purchased is 10,000,000 or less | A&R Subscription Agreement

Business Acquisition

Number of common stock agreed to issued 12,500,000

X

- Definition
The amount of maximum cash consideration under business combination.
+ References
No definition available.
+ Details

Name: dfbhu_BusinessAcquisitionMaximumCashConsideration

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents information pertaining to number of per shares considered for cash consideration.
+ References
No definition available.
+ Details

Name: dfbhu_BusinessCombinationCashConsiderationDividingFactor

Namespace Prefix: dfbhu_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of locations.
+ References
No definition available.
+ Details

Name: dfbhu_MinimumNumberOfLocations

Namespace Prefix: dfbhu_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of deliveries per day.
+ References
No definition available.
+ Details

Name: dfbhu_NumberOfDeliveriesPerDay

Namespace Prefix: dfbhu_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of patients.
+ References
No definition available.
+ Details

Name: dfbhu_NumberOfPatients

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the percentage of shares to be purchased in excess of a certain limit.
+ References
No definition available.
+ Details

Name: dfbhu_PercentageOfSharesToBePurchasedInExcessOfCertainLimit

Namespace Prefix: dfbhu_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of common stock agreed to issued.
+ References
No definition available.
+ Details

Name: dfbhu_StockAgreedToBeIssuedDuringPeriodShares

Namespace Prefix: dfbhu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares owed by acquirer.
+ References
No definition available.
+ Details

Name: dfbhu_StockPreviouslyOwnedByAcquirerNumberOfShares

Namespace Prefix: dfbhu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of common stock transferred during the period.
+ References
No definition available.
+ Details

Name: dfbhu_StockTransferredDuringPeriodShares

Namespace Prefix: dfbhu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the term for restriction from selling, transferring or pledging any securities of the entity.
+ References
No definition available.
+ Details

Name: dfbhu_TermForRestrictionFromSellingTransferringOrPledgingSecuritiesOfEntity

Namespace Prefix: dfbhu_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the term for restriction from selling, transferring or pledging any securities of the entity for certain members.
+ References
No definition available.
+ Details

Name: dfbhu_TermForRestrictionFromSellingTransferringOrPledgingSecuritiesOfEntityForCertainMembers

Namespace Prefix: dfbhu_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of equity interests issued or issuable to acquire entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479
+ Details

Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of states the entity operates in as of the balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfStatesInWhichEntityOperates

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: dfbhu_AgreementAxis=dfbhu_LockUpAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=dfbhu_AdaptHealthHoldingsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dfbhu_AgreementAxis=dfbhu_AssignmentLetterAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=dfbhu_ScenarioSixMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dfbhu_AgreementAxis=dfbhu_RAssignmentLetterAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=dfbhu_ScenarioSevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=dfbhu_DeerfieldPrivateDesignFundIvL.p.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dfbhu_AgreementAxis=dfbhu_SubscriptionAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dfbhu_AgreementAxis=dfbhu_RSubscriptionAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=dfbhu_ScenarioOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=dfbhu_ScenarioThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=dfbhu_ScenarioFourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=dfbhu_ScenarioFiveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=dfbhu_ScenarioEightMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=dfbhu_ScenarioTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.19.3

Related Party Transactions - Services Agreements and Reimbursements (Details) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Statement line items

General and administrative expenses $ 1,195,246 $ 391,160 $ 3,285,654 $ 604,502

CFO

Statement line items

Monthly payment amount 7,500 7,500

Sponsor

Statement line items

Monthly payment amount 10,000 10,000

Administrative Support Agreement Member

Statement line items

General and administrative expenses $ 52,500 $ 52,500 $ 157,500 $ 130,000

X

- Definition
The amount of general and administration expenses payable per month as per agreement.
+ References
No definition available.
+ Details

Name: dfbhu_GeneralAndAdministrativeExpensePayablePerMonth

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefFinancialOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=dfbhu_AdministrativeSupportAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 33 R7.htm IDEA: XBRL DOCUMENT v3.19.3

Description of Organization and Business Operations
9 Months Ended

Sep. 30, 2019

Description of Organization and Business Operations

Description of Organization and Business Operations

Note 1—Description of Organization and Business Operations

DFB Healthcare Acquisitions Corp. (the “Company”) was incorporated in Delaware on November 22, 2017. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). Although the Company is not limited to a particular industry or sector for purposes of consummating a Business Combination, the Company intends to focus its search on the healthcare or healthcare related industries. The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.

As of September 30, 2019, the Company had not commenced any operations. All activity for the period from November 22, 2017 (inception) through September 30, 2019 relates to the Company’s formation, the Company’s initial public offering (the “Initial Public Offering”), and, since the closing of the Initial Public Offering, the search for a prospective initial Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering.

The Company’s sponsor is Deerfield/RAB Ventures, LLC, a Delaware limited liability company (the “Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on February 15, 2018. On February 21, 2018, the Company consummated its Initial Public Offering of 25,000,000 units (each, a “Unit” and collectively, the “Units”) sold to the public at the price of $10.00 per Unit, generating gross proceeds of $250 million and incurring offering costs of approximately $13.06 million, inclusive of $7.875 million in deferred underwriting commissions (Note 5). The underwriter was granted a 45-day option from the date of the final prospectus relating to the Initial Public Offering to purchase up to 3,750,000 additional Units to cover over-allotments, if any, at $10.00 per Unit. The over-allotment option was not exercised prior to its expiration on April 2, 2018.

Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (the “Private Placement”) of 4,333,333 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant to the Sponsor, generating gross proceeds of $6.5 million (Note 4). The Sponsor had agreed that, had the over-allotment option been exercised, the Sponsor would have purchased up to an additional 500,000 Private Placement Warrants at a price of $1.50 per Private Placement Warrant.

Upon the closing of the Initial Public Offering and the Private Placement, $250 million ($10.00 per Unit) of the net proceeds of the sale of the Units in the Initial Public Offering and the Private Placement was placed in a trust account (the “Trust Account”), located in the United States at J.P. Morgan Chase Bank, N.A., with Continental Stock Transfer & Trust Company acting as trustee, and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of paragraphs (d)(2), (d)(3) and (d)(4) of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below.

At September 30, 2019, the Company had approximately $622,000 in cash held outside of the Trust Account. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.

The Company will provide its holders of the outstanding shares of its common stock, par value $0.0001, sold in the Initial Public Offering (the “public stockholders”) with the opportunity to redeem all or a portion of their Public Shares (as defined below in Note 3) upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially at $10.00 per Public Share). The per-share amount to be distributed to public stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5). These Public Shares are recorded at a redemption value and classified as temporary equity in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company decides not to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transactions is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the initial stockholders (as defined below) agreed to vote their Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. The Company’s insiders must: (i) refrain from purchasing shares during certain blackout periods and when they are in possession of any material non-public information and (ii) to clear all trades with the Company’s legal counsel prior to execution. In addition, the initial stockholders agreed to waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of a Business Combination.

Notwithstanding the foregoing, the Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the common stock sold in the Initial Public Offering, without the prior consent of the Company.

The Company’s Sponsor, officers and directors (the “initial stockholders”) agreed not to propose an amendment to the Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the public stockholders with the opportunity to redeem their shares of common stock in conjunction with any such amendment.

If the Company is unable to complete a Business Combination within 24 months from the closing of the Initial Public Offering, or February 21, 2020 (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest (less up to $50,000 of interest to pay dissolution expenses, which interest shall be net of taxes payable by the Company and any amounts released to the Company to fund working capital requirements, subject to an annual limit of $250,000), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.

The initial stockholders agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the initial stockholders should acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to their deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be less than the $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a definitive agreement for a Business Combination, reduce the amount of funds in the Trust Account to below (i) $10.00 per Public Share or (ii) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company has sought and will continue to seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

On July 8, 2019, the Company, AdaptHealth Holdings LLC, a Delaware limited liability company (“Adapt”), BM AH Holdings, LLC, a Delaware limited liability company, Access Point Medical, Inc., a Delaware corporation, DFB Merger Sub LLC, a Delaware limited liability company, AH Representative LLC, a Delaware limited liability company, and, solely for the limited purposes set forth therein, BlueMountain Foinaven Master Fund L.P., a Cayman Islands exempted limited partnership, BMSB L.P., a Delaware limited partnership, BlueMountain Fursan Fund L.P., a Cayman Islands exempted limited partnership, and Clifton Bay Offshore Investments, L.P., a British Virgin Islands limited partnership (collectively, the “Blocker Sellers”), entered into an Agreement and Plan of Merger (the “Agreement”), which was later amended on October 15, 2019, pursuant to which the Company agreed to combine with Adapt in a transaction (the “Transaction”) that will result in Adapt becoming a partially owned subsidiary of the Company. It is anticipated that the Company will change its name to AdaptHealth Corp. upon the consummation of the Transaction (Note 8).

Liquidity and Going Concern

In connection with the Company’s assessment of going concern considerations in accordance with FASB’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” the Company’s management has determined that the mandatory liquidation and subsequent dissolution raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after February 21, 2020.

Through September 30, 2019, the Company's liquidity needs have been satisfied through receipt of a $25,000 capital contribution from the Sponsor in exchange for the issuance of the Founder Shares (Note 4) to the Sponsor, $270,531 in loans from the Sponsor (which was fully repaid on February 21, 2018), the proceeds from the consummation of the Private Placement not held in the Trust Account, and interest withdrawn from the Trust Account for working capital and tax purposes. The Company withdrew approximately $1.4 million and $666,000 of interest income from the Trust Account during the nine months ended September 30, 2019 and 2018, respectively to pay for tax obligations and working capital purposes. Of the $1.4 million of interest income withdrawn in 2019, $250,000 was for working capital.

As of September 30, 2019, the Company had approximately $622,000 in its operating bank account, and approximately $5.9 million of interest income available to fund a Business Combination (which interest shall be net of taxes payable by the Company and any amounts, subject to an annual limit of $250,000, released to the Company to fund working capital requirements), and a working capital deficit of approximately $2.4 million. In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”) (see Note 4). The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. Based on the foregoing, the Company may have insufficient funds available to operate its business through February 21, 2020. Following the initial Business Combination, if cash on hand is insufficient, the Company may need to obtain additional financing in order to meet its obligations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. The Company's plans to raise capital or to consummate the initial Business Combination may not be successful. These matters, among others, raise substantial doubt about the Company's ability to continue as a going concern.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R3.htm IDEA: XBRL DOCUMENT v3.19.3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares

Sep. 30, 2019

Dec. 31, 2018

Stockholders' Equity:

Temporary stock, par value (in dollars per share) $ 0.0001 $ 0.0001

Temporary stock, shares outstanding (in shares) 24,055,352 24,054,988

Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001

Preferred stock, shares authorized (in shares) 1,000,000 1,000,000

Preferred stock, shares issued (in shares) 0 0

Preferred stock, shares outstanding (in shares) 0 0

Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001

Common stock, shares authorized (in shares) 200,000,000 200,000,000

Common stock, shares issued (in shares) 7,194,648 7,195,012

Common stock, shares outstanding (in shares) 7,194,648 7,195,012

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (27)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquityParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 35 R17.htm IDEA: XBRL DOCUMENT v3.19.3

Description of Organization and Business Operations (Details) - USD ($)
3 Months Ended 9 Months Ended

Feb. 21, 2018

Dec. 15, 2017

Mar. 31, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Feb. 15, 2018

Description of Organization and Business Operations

Units issued (in units) $ 236,939,488

Offer price (in dollars per unit) $ 10.00

Proceeds received from initial public offering $ 250,000,000

Deferred underwriting commissions charged to equity in connection with the initial public offering 7,875,000

Proceeds received from private placement 6,500,000

Aggregate fair value of assets held in Trust Account (as a percent) 80.00%

Acquisition of outstanding voting securities (as a percent) 50.00%

Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001 $ 0.0001

Net tangible assets $ 5,000,001

Restriction on redemption of common stock sold (as a percent) 15.00%

Redemption obligation of shares upon non completion of business combination (as a percent) 100.00%

Term to complete business combination 24 months

Number of business days to redeem public shares 10 days

Maximum reduction in interest to pay dissolution expenses $ 50,000

Annual limit of amount released to the Company to fund working capital requirements $ 250,000

Redemption price (in dollars per share) $ 10.00

Working Capital $ 250,000

Cash Held Outside of Trust Account 622,000 622,000

Interest available 5,900,000

Interest withdrawn from Trust Account 1,448,533 665,756

Working capital deficit $ 2,400,000

Sponsor

Description of Organization and Business Operations

Offer price (in dollars per unit) $ 1.50

Common stock, par value (in dollars per share) $ 0.0001

Proceeds from issuance of common stock to Sponsor $ 25,000 $ 25,000

Loan from related party $ 270,531 270,531

Interest withdrawn from Trust Account $ 1,400,000 $ 666,000

IPO

Description of Organization and Business Operations

Units issued (in units) $ 25,000,000

Offer price (in dollars per unit) $ 10.00

Proceeds received from initial public offering $ 250,000,000

Offering costs 13,060,000

Deferred underwriting commissions charged to equity in connection with the initial public offering 7,875,000

Private Placement Warrants | Sponsor

Description of Organization and Business Operations

Units issued (in units) $ 4,333,333

Offer price (in dollars per unit) $ 1.50

Proceeds received from private placement $ 6,500,000

Additional warrants available (in warrants) 500,000

Over-Allotment Option

Description of Organization and Business Operations

Underwriting option term 45 days

Offer price (in dollars per unit) $ 10.00

Number of additional units to be purchased to cover over-allotment 3,750,000

X

- Definition
Amount of annual ceiling of amount released to the Company for funding working capital requirements.
+ References
No definition available.
+ Details

Name: dfbhu_AnnualCeilingOfAmountReleasedToCompanyForFundingWorkingCapitalRequirements

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash held by the entity outside of the Trust Account.
+ References
No definition available.
+ Details

Name: dfbhu_CashHeldOutsideOfTrustAccount

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of deferred underwriting commissions in connection with the initial public offering in noncash investing or financing activities.
+ References
No definition available.
+ Details

Name: dfbhu_DeferredUnderwritingCommissions

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with Interest released from trust account.
+ References
No definition available.
+ Details

Name: dfbhu_InterestReleasedFromTrustAccount

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of maximum reduction in interest to pay dissolution expenses.
+ References
No definition available.
+ Details

Name: dfbhu_MaximumReductionInInterestForPaymentOfDissolutionExpenses

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current assets less current liabilities.
+ References
No definition available.
+ Details

Name: dfbhu_NetCurrentAssets

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of net tangible assets of target company as a condition for proceeding with business combinations.
+ References
No definition available.
+ Details

Name: dfbhu_NetTangibleAssetsOfTargetCompanyForProceedingWithBusinessCombination

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of additional units to be purchased to cover over-allotment.
+ References
No definition available.
+ Details

Name: dfbhu_NumberOfAdditionalUnitsToBePurchasedToCoverOverAllotment

Namespace Prefix: dfbhu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of additional warrants to be purchased by Sponsor upon exercise of over-allotment.
+ References
No definition available.
+ Details

Name: dfbhu_NumberOfAdditionalWarrantsToBePurchasedUponExerciseOfOverAllotment

Namespace Prefix: dfbhu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of business days for redemption of shares.
+ References
No definition available.
+ Details

Name: dfbhu_NumberOfBusinessDaysForRedemptionOfShares

Namespace Prefix: dfbhu_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of offering costs incurred for Initial Public Offering.
+ References
No definition available.
+ Details

Name: dfbhu_OfferingCostsInitialPublicOffering

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Percentage of acquisition of outstanding voting securities post initial business combination transaction of the target company.
+ References
No definition available.
+ Details

Name: dfbhu_PercentageOfAcquisitionOfOutstandingVotingSecurities

Namespace Prefix: dfbhu_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Percentage of aggregate fair value of assets held in Trust Account to complete initial business combinations.
+ References
No definition available.
+ Details

Name: dfbhu_PercentageOfAggregateFairValueOfAssetsHeldInTrustAccountToCompleteInitialBusinessCombinations

Namespace Prefix: dfbhu_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Percentage of redemption obligation of shares upon non completion of business combination.
+ References
No definition available.
+ Details

Name: dfbhu_PercentageOfRedemptionObligationOfSharesUponNonCompletionOfBusinessCombination

Namespace Prefix: dfbhu_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Percentage of restriction on redemption of common stock sold as per the Amended and Restated Certificate of Incorporation.
+ References
No definition available.
+ Details

Name: dfbhu_PercentageOfRestrictionOnRedemptionOfCommonStockSold

Namespace Prefix: dfbhu_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount to be paid per public share by entity upon redemption.
+ References
No definition available.
+ Details

Name: dfbhu_PublicSharesRedemptionPricePerShare

Namespace Prefix: dfbhu_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Per unit amount received for each capital unit issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: dfbhu_SaleOfStockPricePerUnit

Namespace Prefix: dfbhu_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Term to complete business combination from closing of Initial Public Offering.
+ References
No definition available.
+ Details

Name: dfbhu_TermToCompleteBusinessCombinationFromClosingOfProposedPublicOffering

Namespace Prefix: dfbhu_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The term of underwriting agreement , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: dfbhu_UnderwritersOptionTerm

Namespace Prefix: dfbhu_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the working capital deficit of the entity.
+ References
No definition available.
+ Details

Name: dfbhu_WorkingCapitalDeficit

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_CapitalUnitLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.23)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableRelatedPartiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash inflow associated with the amount received from entity's first offering of stock to the public.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=dfbhu_PrivatePlacementWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R13.htm IDEA: XBRL DOCUMENT v3.19.3

Fair Value Measurements
9 Months Ended

Sep. 30, 2019

Fair Value Measurements

Fair Value Measurements

Note 7—Fair Value Measurements

The following table presents information about the Company’s assets that are measured on a recurring basis as of September 30, 2019 and December 31, 2018 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value.

September 30, 2019



Quoted Prices



Significant Other



Significant Other

in Active Markets

Observable Inputs

Unobservable Inputs

Description

(Level 1)

(Level 2)

(Level 3)

Cash and marketable securities held in Trust Account

$

255,880,268

December 31, 2018



Quoted Prices



Significant Other



Significant Other

in Active Markets

Observable Inputs

Unobservable Inputs

Description

(Level 1)

(Level 2)

(Level 3)

Cash and marketable securities held in Trust Account

$

253,019,179





Approximately $1,300 and $900 of the balance in the Trust Account was held in cash as of September 30, 2019 and December 31, 2018, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-URI http://asc.fasb.org/topic&trid=2155941
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R6.htm IDEA: XBRL DOCUMENT v3.19.3

UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS - USD ($)
9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Cash Flows from Operating Activities:

Net income $ 3,637 $ 1,428,480

Adjustments to reconcile net income to net cash used in operating activities:

Interest income in cash and marketable securities held in Trust Account (4,309,622) (2,726,376)

Changes in operating assets and liabilities:

Prepaid expenses 33,537 (240,037)

Accounts payable (12,099) (46,400)

Accrued expenses 2,624,621 202,217

Franchise tax payable (113,543) 112,212

Net cash used in operating activities (1,773,469) (1,269,904)

Cash Flows from Investing Activities:

Principal deposited in Trust Account (250,000,000)

Interest released from Trust Account 1,448,533 665,756

Net cash provided by (used in) investing activities 1,448,533 (249,334,244)

Cash Flows from Financing Activities:

Proceeds from notes payable to related parties 96,291

Repayment of notes payable to related parties (270,531)

Proceeds received from initial public offering 250,000,000

Payment of offering costs (4,994,717)

Proceeds received from private placement 6,500,000

Net cash provided by financing activities 251,331,043

Net change in cash and cash equivalents (324,936) 726,895

Cash and cash equivalents - beginning of the period 947,098 119,821

Cash and cash equivalents - end of the period 622,162 846,716

Supplemental disclosure of noncash investing and financing activities:

Deferred underwriting commissions charged to equity in connection with the initial public offering 7,875,000

Deferred offering costs charged to equity upon completion of the initial public offering 190,795

Value of common stock subject to possible redemption 238,497,140

Change in value of common stock subject to possible redemption 3,640 876,810

Founder shares forfeited 94

Supplemental disclosures of cash flow information:

Cash paid for income taxes $ 934,925 $ 630,000

X

- Definition
The amount of change in common stock value subject to possible redemption in noncash investing or financing activities.
+ References
No definition available.
+ Details

Name: dfbhu_ChangeInCommonStockValueSubjectToPossibleRedemption

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of common stock subject to possible redemption in noncash investing or financing activities.
+ References
No definition available.
+ Details

Name: dfbhu_CommonStockSubjectToPossibleRedemption

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Deferred offering costs charged to equity in noncash investing or financing activities.
+ References
No definition available.
+ Details

Name: dfbhu_DeferredOfferingCostsChargedToEquity

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of deferred underwriting commissions in connection with the initial public offering in noncash investing or financing activities.
+ References
No definition available.
+ Details

Name: dfbhu_DeferredUnderwritingCommissions

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of founder shares forfeited.
+ References
No definition available.
+ Details

Name: dfbhu_FounderSharesForfeited

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period of Franchise taxes owed but not paid.
+ References
No definition available.
+ Details

Name: dfbhu_IncreaseDecreaseInFranchiseTaxes

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with Interest released from trust account.
+ References
No definition available.
+ Details

Name: dfbhu_InterestReleasedFromTrustAccount

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest held in trust account.
+ References
No definition available.
+ Details

Name: dfbhu_InvestmentIncomeInterestHeldInTrustAccount

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with principal deposited in trust account.
+ References
No definition available.
+ Details

Name: dfbhu_PrincipalDepositedInTrustAccount

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585
+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's first offering of stock to the public.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R2.htm IDEA: XBRL DOCUMENT v3.19.3

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)

Sep. 30, 2019

Dec. 31, 2018

Current assets:

Cash and cash equivalents $ 622,162 $ 947,098

Prepaid expenses 124,468 158,005

Total current assets 746,630 1,105,103

Cash and marketable securities held in Trust Account 255,880,268 253,019,179

Total assets 256,626,898 254,124,282

Current liabilities:

Accounts payable 28,675 40,774

Accrued expenses 3,125,000 500,379

Franchise tax payable 44,697 158,240

Total current liabilities 3,198,372 699,393

Deferred underwriting commissions 7,875,000 7,875,000

Total liabilities 11,073,372 8,574,393

Commitments and Contingencies

Common stock, $0.0001 par value; 24,055,352 and 24,054,988 shares subject to possible redemption at September 30, 2019 and December 31, 2018, respectively 240,553,520 240,549,880

Stockholders' Equity:

Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding

Common stock, $0.0001 par value; 200,000,000 shares authorized; 7,194,648 and 7,195,012 shares issued and outstanding (excluding 24,055,352 and 24,054,988 shares subject to possible redemption) at September 30, 2019 and December 31, 2018, respectively 719 720

Additional paid-in capital 2,910,249 2,913,888

Retained earnings 2,089,038 2,085,401

Total stockholders' equity 5,000,006 5,000,009

Total Liabilities and Stockholders' Equity $ 256,626,898 $ 254,124,282

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions held in trust account classified as non-current.
+ References
No definition available.
+ Details

Name: dfbhu_CashAndCashEquivalentsHeldInTrustAccount

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The noncurrent portion of deferred underwriting commission as of balance sheet date.
+ References
No definition available.
+ Details

Name: dfbhu_DeferredUnderwritingCommissionsNoncurrent

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable for franchise taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
No definition available.
+ Details

Name: dfbhu_FranchiseTaxesPayableCurrent

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.27(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 39 R16.htm IDEA: XBRL DOCUMENT v3.19.3

Fair Value Measurements (Tables)
9 Months Ended

Sep. 30, 2019

Fair Value Measurements

Schedule of financial assets measured at fair value

The following table presents information about the Company’s assets that are measured on a recurring basis as of September 30, 2019 and December 31, 2018 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value.

September 30, 2019



Quoted Prices



Significant Other



Significant Other

in Active Markets

Observable Inputs

Unobservable Inputs

Description

(Level 1)

(Level 2)

(Level 3)

Cash and marketable securities held in Trust Account

$

255,880,268

December 31, 2018



Quoted Prices



Significant Other



Significant Other

in Active Markets

Observable Inputs

Unobservable Inputs

Description

(Level 1)

(Level 2)

(Level 3)

Cash and marketable securities held in Trust Account

$

253,019,179





X

- Definition
Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R12.htm IDEA: XBRL DOCUMENT v3.19.3

Stockholders' Equity
9 Months Ended

Sep. 30, 2019

Stockholders' Equity

Stockholders' Equity

Note 6—Stockholders’ Equity

Common Stock—On February 15, 2018, the Company filed its Amended and Restated Certificate of Incorporation to increase its number of authorized common stock to 200,000,000 shares with a par value of $0.0001 per share. Holders of common stock are entitled to one vote for each share. As of September 30, 2019 and December 31, 2018, there were 31,250,000 shares of common stock outstanding, including 24,055,352 and 24,054,988 shares of common stock subject to possible redemption, respectively,

Preferred Stock—The Company is authorized to issue 1,000,000 shares of preferred stock, par value $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2019 and December 31, 2018, there were no shares of preferred stock issued or outstanding.

Warrants—Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable 30 days after the completion of a Business Combination; provided that the Company has an effective registration statement under the Securities Act covering the common stock issuable upon exercise of the Public Warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their Public Warrants on a cashless basis and such cashless exercise is exempt from registration under the Securities Act). The Company has agreed that as soon as practicable, but in no event later than 20 business days, after the closing of a Business Combination, the Company will use its best efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the common stock issuable upon exercise of the Public Warrants. The Company will use its best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the Public Warrants in accordance with the provisions of the warrant agreement. If a registration statement covering the common stock issuable upon exercise of the warrants is not effective by the sixtieth (60th) day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the common stock issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be non-redeemable so long as they are held by the initial purchasers or such purchasers’ permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

The Company may call the Public Warrants for redemption (except with respect to the Private Placement Warrants):

·

in whole and not in part;

·

at a price of $0.01 per warrant;

·

upon a minimum of 30 days’ prior written notice of redemption; and

·

if, and only if, the last reported sales price of the common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement.

The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrant shares. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R24.htm IDEA: XBRL DOCUMENT v3.19.3

Fair Value Measurements (Details) - USD ($)

Sep. 30, 2019

Dec. 31, 2018

Fair value measurements, recurring and nonrecurring, valuation techniques

Cash and marketable securities held in Trust Account $ 255,880,268 $ 253,019,179

Trust account held in cash 1,300 900

Fair value measurements, (Recurring) | Level 1

Fair value measurements, recurring and nonrecurring, valuation techniques

Cash and marketable securities held in Trust Account $ 255,880,268 $ 253,019,179

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions held in trust account classified as non-current.
+ References
No definition available.
+ Details

Name: dfbhu_CashAndCashEquivalentsHeldInTrustAccount

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of trust account held in cash.
+ References
No definition available.
+ Details

Name: dfbhu_TrustAccountHeldInCash

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R20.htm IDEA: XBRL DOCUMENT v3.19.3

Related Party Transactions (Details) - USD ($)
2 Months Ended 9 Months Ended

Apr. 02, 2018

Feb. 21, 2018

Dec. 15, 2017

Jan. 31, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Feb. 15, 2018

Related Party Transactions

Shares issued (in shares) 7,194,648 7,195,012

Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001 $ 0.0001

Minimum period for not to transfer, assign or sell of any shares 30 days

Offer price (in dollars per unit) $ 10.00

Proceeds received from private placement $ 6,500,000

Outstanding borrowings under working capital loans $ 0

Sponsor

Related Party Transactions

Shares issued (in shares) 7,187,500

Common stock, par value (in dollars per share) $ 0.0001

Proceeds from issuance of common stock to Sponsor $ 25,000 $ 25,000

Shares subject to forfeiture 937,500

Forfeiture adjusted percentage to issued and outstanding shares 20.00%

Number of shares forfeited 937,500

Minimum period for not to transfer, assign or sell of any shares 1 year

Minimum price for not to transfer, assign or sell of any founder shares $ 12.00

Number of trading days considered in a period of 30 trading days for minimum price alternative 20 days

Minimum period for considering price per share alternative 150 days

Offer price (in dollars per unit) $ 1.50

Loan from related party $ 270,531 $ 270,531

Maximum working capital loans may be converted to warrants $ 1,500,000

Sponsor | Private Placement Warrants

Related Party Transactions

Price Per Warrant $ 1.50

Warrants issued (in warrants) 4,333,333

Proceeds received from private placement $ 6,500,000

Number of Additional Warrants to be Purchased upon Exercise of Over-allotment 500,000

Issued Price of Additional Warrants $ 1.50

Proceeds to be received upon additional warrants exercised $ 750,000

Common stock exercisable for each warrant 1

Exercise price of warrants $ 11.50

CFO

Related Party Transactions

Founder shares transferred 100,000

Independent directors

Related Party Transactions

Founder shares transferred 30,000

Deerfield Management

Related Party Transactions

Shares issued (in shares) 2,500,000

Price per unit 10.00

X

- Definition
The forfeiture will be adjusted to the extent that the over-allotment option is not exercised in full by the underwriters. So the percentage of issued and outstanding shares adjusted after initial public offer.
+ References
No definition available.
+ Details

Name: dfbhu_ForfeitureAdjustedPercentageToIssuedAndOutstandingShares

Namespace Prefix: dfbhu_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Issued price of additional warrants.
+ References
No definition available.
+ Details

Name: dfbhu_IssuedPriceOfAdditionalWarrants

Namespace Prefix: dfbhu_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares included in common stock subject to forfeiture.
+ References
No definition available.
+ Details

Name: dfbhu_MaximumSharesSubjectToForfeiture

Namespace Prefix: dfbhu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The amount of maximum working capital loans may be converted to warrants.
+ References
No definition available.
+ Details

Name: dfbhu_MaximumWorkingCapitalLoansMayBeConvertedToWarrants

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Minimum period considering price per share alternative from the date of initial business combination.
+ References
No definition available.
+ Details

Name: dfbhu_MinimumPeriodForConsideringPricePerShareAlternative

Namespace Prefix: dfbhu_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Minimum period for not to transfer, assign or sell of any shares agreed by initial stockholders.
+ References
No definition available.
+ Details

Name: dfbhu_MinimumPeriodForNotToTransferAssignOrSellOfAnyFounderShares

Namespace Prefix: dfbhu_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Minimum price for not to transfer, assign or sell of any founder shares agreed by initial stockholders.
+ References
No definition available.
+ Details

Name: dfbhu_MinimumPriceForNotToTransferAssignOrSellOfAnyFounderShares

Namespace Prefix: dfbhu_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of additional warrants to be purchased by Sponsor upon exercise of over-allotment.
+ References
No definition available.
+ Details

Name: dfbhu_NumberOfAdditionalWarrantsToBePurchasedUponExerciseOfOverAllotment

Namespace Prefix: dfbhu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares forfeited due to over allotment option expired.
+ References
No definition available.
+ Details

Name: dfbhu_NumberOfSharesForfeited

Namespace Prefix: dfbhu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares transferred by sponsor to initial stockholders.
+ References
No definition available.
+ Details

Name: dfbhu_NumberOfSharesTransferredBySponsorToInitialStockholders

Namespace Prefix: dfbhu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of trading days considered in a period of 30 trading days for minimum price evaluation.
+ References
No definition available.
+ Details

Name: dfbhu_NumberOfTradingDaysConsideredInPeriodOf30TradingDaysForMinimumPriceAlternative

Namespace Prefix: dfbhu_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of borrowings outstanding under working capital loans.
+ References
No definition available.
+ Details

Name: dfbhu_OutstandingBorrowingsUnderWorkingCapitalLoans

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Issued price per warrant.
+ References
No definition available.
+ Details

Name: dfbhu_PricePerWarrant

Namespace Prefix: dfbhu_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Proceeds to be received upon exercise of additional warrants.
+ References
No definition available.
+ Details

Name: dfbhu_ProceedsToBeReceivedUponAdditionalWarrantsExercised

Namespace Prefix: dfbhu_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per unit amount received for each capital unit issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: dfbhu_SaleOfStockPricePerUnit

Namespace Prefix: dfbhu_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.23)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableRelatedPartiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=dfbhu_PrivatePlacementWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefFinancialOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

Stockholders' Equity (Details)	9 Months Ended
Stockholders' Equity (Details)	Sep. 30, 2019 $ / shares shares	Dec. 31, 2018 $ / shares shares	Feb. 15, 2018 Vote $ / shares shares
Stockholders' Equity
Common stock, shares authorized (in shares)	200,000,000	200,000,000	200,000,000
Common stock, par value (in dollars per share) \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Number of votes per common stock \| Vote			1
Common stock, shares outstanding including shares subject to possible redemption (in shares)	31,250,000	31,250,000
Temporary stock, shares outstanding (in shares)	24,055,352	24,054,988
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, par value (in dollars per share) \| $ / shares	$ 0.0001	$ 0.0001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Exercisable period after the completion of a Business Combination	30 days
Agreed duration to file registration with SEC	20 days
Warrant expiration period	5 years
Warrant non transferable period	30 days
Redemption price of warrant \| $ / shares	$ 0.01
Prior notice period	30 days
Minimum closing price of ordinary share \| $ / shares	$ 18.00
Number of trading days price must be equal or above target price	20 days
Total number of trading days	30 days

Commitments & Contingencies	9 Months Ended
Commitments & Contingencies	Sep. 30, 2019
Commitments & Contingencies
Commitments & Contingencies	Note 5—Commitments & Contingencies Registration Rights The holders of Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans, if any, and any shares of common stock underlying such securities, will be entitled to registration rights pursuant to a registration rights agreement entered into on February 15, 2018. These holders will be entitled to certain demand and “piggyback” registration rights. However, the registration rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until the termination of the applicable lock-up period for the securities to be registered. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company granted the underwriters a 45-day option from the date of the final prospectus relating to the Initial Public Offering to purchase up to 3,750,000 additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. The option expired on April 2, 2018. The underwriters were entitled to an underwriting discount of $0.20 per Unit, or $4.5 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per Unit, or $7.875 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. The underwriters did not receive any underwriting discounts or commissions on the 2,500,000 Units purchased by Deerfield Management in the Initial Public Offering.

Public Offering (Details) - USD ($)		3 Months Ended
Public Offering (Details) - USD ($)	Feb. 21, 2018	Mar. 31, 2018	Sep. 30, 2019
Description of Organization and Business Operations
Units issued (in units)		$ 236,939,488
Offer price (in dollars per unit)			$ 10.00
IPO
Description of Organization and Business Operations
Units issued (in units)	$ 25,000,000
Price per unit	10.00
Offer price (in dollars per unit)	$ 10.00
Shares in single unit (in shares)	1
Number of warrants comprised in each unit	0.33
Common stock exercisable for each warrant	1
Exercise price of warrants	$ 11.50

UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Common Stock	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Total
Balance at Dec. 31, 2017	$ 719	$ 24,281	$ (693)	$ 24,307
Balance (in shares) at Dec. 31, 2017	7,187,500
Sale of units in initial public offering, net of offering costs	$ 2,500	236,936,988		236,939,488
Sale of units in initial public offering, net of offering costs (in shares)	25,000,000
Sale of private placement warrants to Sponsor in private placement		6,500,000		6,500,000
Common stock subject to possible redemption	$ (2,387)	(238,681,733)		(238,684,120)
Common stock subject to possible redemption (in shares)	(23,868,412)
Net income (loss)			220,333	220,333
Balance at Mar. 31, 2018	$ 832	4,779,536	219,640	5,000,008
Balance (in shares) at Mar. 31, 2018	8,319,088
Balance at Dec. 31, 2017	$ 719	24,281	(693)	24,307
Balance (in shares) at Dec. 31, 2017	7,187,500
Net income (loss)				1,428,480
Balance at Sep. 30, 2018	$ 726	3,571,492	1,427,787	5,000,005
Balance (in shares) at Sep. 30, 2018	7,260,773
Balance at Mar. 31, 2018	$ 832	4,779,536	219,640	5,000,008
Balance (in shares) at Mar. 31, 2018	8,319,088
Founder shares forfeited	$ (94)	94
Founder shares forfeited (in shares)	(937,500)
Common stock subject to possible redemption	$ (7)	(689,823)		(689,830)
Common stock subject to possible redemption (in shares)	(68,983)
Net income (loss)			689,830	689,830
Balance at Jun. 30, 2018	$ 731	4,089,807	909,470	5,000,008
Balance (in shares) at Jun. 30, 2018	7,312,605
Common stock subject to possible redemption	$ (5)	(518,315)		(518,320)
Common stock subject to possible redemption (in shares)	(51,832)
Net income (loss)			518,317	518,317
Balance at Sep. 30, 2018	$ 726	3,571,492	1,427,787	5,000,005
Balance (in shares) at Sep. 30, 2018	7,260,773
Balance at Dec. 31, 2018	$ 720	2,913,888	2,085,401	$ 5,000,009
Balance (in shares) at Dec. 31, 2018	7,195,012			7,195,012
Common stock subject to possible redemption	$ (9)	(825,591)		$ (825,600)
Common stock subject to possible redemption (in shares)	(82,560)
Net income (loss)			825,598	825,598
Balance at Mar. 31, 2019	$ 711	2,088,297	2,910,999	5,000,007
Balance (in shares) at Mar. 31, 2019	7,112,452
Balance at Dec. 31, 2018	$ 720	2,913,888	2,085,401	$ 5,000,009
Balance (in shares) at Dec. 31, 2018	7,195,012			7,195,012
Net income (loss)				$ 3,637
Balance at Sep. 30, 2019	$ 719	2,910,249	2,089,038	$ 5,000,006
Balance (in shares) at Sep. 30, 2019	7,194,648			7,194,648
Balance at Mar. 31, 2019	$ 711	2,088,297	2,910,999	$ 5,000,007
Balance (in shares) at Mar. 31, 2019	7,112,452
Common stock subject to possible redemption	$ 7	667,483		667,490
Common stock subject to possible redemption (in shares)	66,749
Net income (loss)			(667,488)	(667,488)
Balance at Jun. 30, 2019	$ 718	2,755,780	2,243,511	5,000,009
Balance (in shares) at Jun. 30, 2019	7,179,201
Common stock subject to possible redemption	$ 1	154,469		154,470
Common stock subject to possible redemption (in shares)	15,447
Net income (loss)			(154,473)	(154,473)
Balance at Sep. 30, 2019	$ 719	$ 2,910,249	$ 2,089,038	$ 5,000,006
Balance (in shares) at Sep. 30, 2019	7,194,648			7,194,648

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Nov. 05, 2019
Document and Entity Information
Entity Registrant Name	DFB Healthcare Acquisitions Corp.
Entity Central Index Key	0001725255
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		31,250,000
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3

Public Offering	9 Months Ended
Public Offering	Sep. 30, 2019
Public Offering
Public Offering	Note 3—Public Offering On February 21, 2018, the Company sold 25,000,000 Units at a price of $10.00 per Unit in the Initial Public Offering. Each Unit consists of one share of common stock (such shares of common stock included in the Units being offered, the “Public Shares”), and one-third of one redeemable warrant (each, a “Public Warrant”). Each Public Warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment (see Note 6).

Merger Agreement (Details) $ / shares in Units, $ in Millions			9 Months Ended
	Oct. 15, 2019 $ / shares shares	Jul. 08, 2019 USD ($) item $ / shares shares	Sep. 30, 2019 USD ($) shares
Lock-up Agreement
Business Acquisition
Term for restriction from selling, transferring or pledging any securities of the Company			9 months
Adapt
Business Acquisition
Total Merger Consideration \| $			$ 515.0
Cash Consideration Dividing Factor (in dollars per share) \| $ / shares		$ 10.00
Number Of Deliveries Per Day \| item		7,000
States of Operation		49
Number of Locations		150
Adapt \| Assignment Letter Agreement
Business Acquisition
Shares of the Company's common stock issued		2,500,000
Warrants to purchase shares of common stock		1,733,333
Number of shares for each warrant			0.333
Adapt \| Subsequent Event \| Shares purchased is 10,000,000 or less \| A&R Assignment Letter Agreement
Business Acquisition
Shares of the Company's common stock issued	2,500,000
Warrants to purchase shares of common stock	1,733,333
Adapt \| Subsequent Event \| Shares purchased is 12,500,000 \| A&R Assignment Letter Agreement
Business Acquisition
Shares of the Company's common stock issued	2,437,500
Warrants to purchase shares of common stock	1,690,000
Deerfield \| Subscription Agreement
Business Acquisition
Term for restriction from selling, transferring or pledging any securities of the Company		9 months
Purchase price \| $ / shares		$ 10.00
Number of shares owed by acquirer		2,500,000
Deerfield \| Subsequent Event \| A&R Subscription Agreement
Business Acquisition
Shares of the Company's common stock issued	7,500,000
Deerfield \| Subsequent Event \| Available Cash is $75 million or less \| A&R Subscription Agreement
Business Acquisition
Number of common stock agreed to issued	12,500,000
Deerfield \| Subsequent Event \| Available Cash is between $100 million and $200 million \| A&R Subscription Agreement
Business Acquisition
Number of common stock agreed to issued	10,000,000
Deerfield \| Subsequent Event \| Available Cash is more than $200 million \| A&R Subscription Agreement
Business Acquisition
Number of common stock agreed to issued	300,000,000
Purchase price \| $ / shares	$ 10
Deerfield \| Subsequent Event \| Total number of Shares to be purchased is more than 10,000,000 \| A&R Subscription Agreement
Business Acquisition
Number of common stock agreed to issued	10,000,000
Percentage of shares to be purchased in excess of 10000000	96
Minimum \| Lock-up Agreement
Business Acquisition
Term for restriction from selling, transferring or pledging any securities of the Company for certain members of adapt			3 months
Minimum \| Subsequent Event \| A&R Subscription Agreement
Business Acquisition
Term for restriction from selling, transferring or pledging any securities of the Company	3 months
Minimum \| Subsequent Event \| A&R Assignment Letter Agreement
Business Acquisition
Warrants to purchase shares of common stock	1,690,000
Minimum \| Adapt \| Subsequent Event \| A&R Assignment Letter Agreement
Business Acquisition
Shares of the Company's common stock issued	2,437,500
Minimum \| Adapt \| Subsequent Event \| Shares purchased is more than 10,000,000 but less than 12,500,000 \| A&R Assignment Letter Agreement
Business Acquisition
Shares of the Company's common stock issued	10,000,000
Minimum \| Deerfield \| Subscription Agreement
Business Acquisition
Number of common stock agreed to issued		5,000,000
Minimum \| Deerfield \| Subsequent Event \| A&R Subscription Agreement
Business Acquisition
Number of common stock agreed to issued	5,000,000
Minimum \| Deerfield \| Subsequent Event \| Available Cash is more than $75 million but less than $100 million \| A&R Subscription Agreement
Business Acquisition
Number of common stock agreed to issued	10,000,000
Minimum \| Deerfield \| Subsequent Event \| Shares purchased is 10,000,000 or less \| A&R Subscription Agreement
Business Acquisition
Number of common stock agreed to issued	5,000,000
Maximum \| Lock-up Agreement
Business Acquisition
Term for restriction from selling, transferring or pledging any securities of the Company for certain members of adapt			6 months
Maximum \| Subsequent Event \| A&R Subscription Agreement
Business Acquisition
Term for restriction from selling, transferring or pledging any securities of the Company	9 months
Maximum \| Subsequent Event \| A&R Assignment Letter Agreement
Business Acquisition
Warrants to purchase shares of common stock	1,733,333
Maximum \| Adapt
Business Acquisition
Common Stock issued as per Merger Agreement (in shares)		51,500,000
Maximum Cash Consideration \| $		$ 50.0
Number of Patients \| $		$ 1.0
Maximum \| Adapt \| Subsequent Event \| A&R Assignment Letter Agreement
Business Acquisition
Shares of the Company's common stock issued	2,500,000
Maximum \| Deerfield \| Subscription Agreement
Business Acquisition
Number of common stock agreed to issued		10,000,000
Maximum \| Deerfield \| Subsequent Event \| A&R Subscription Agreement
Business Acquisition
Number of common stock agreed to issued	12,500,000
Maximum \| Deerfield \| Subsequent Event \| Available Cash is more than $75 million but less than $100 million \| A&R Subscription Agreement
Business Acquisition
Number of common stock agreed to issued	12,500,000
Maximum \| Deerfield \| Subsequent Event \| Shares purchased is 10,000,000 or less \| A&R Subscription Agreement
Business Acquisition
Number of common stock agreed to issued	12,500,000

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Stockholders' Equity:
Temporary stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Temporary stock, shares outstanding (in shares)	24,055,352	24,054,988
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	7,194,648	7,195,012
Common stock, shares outstanding (in shares)	7,194,648	7,195,012

Description of Organization and Business Operations (Details) - USD ($)			3 Months Ended	9 Months Ended
	Feb. 21, 2018	Dec. 15, 2017	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Feb. 15, 2018
Description of Organization and Business Operations
Units issued (in units)			$ 236,939,488
Offer price (in dollars per unit)				$ 10.00
Proceeds received from initial public offering					$ 250,000,000
Deferred underwriting commissions charged to equity in connection with the initial public offering					7,875,000
Proceeds received from private placement					6,500,000
Aggregate fair value of assets held in Trust Account (as a percent)				80.00%
Acquisition of outstanding voting securities (as a percent)				50.00%
Common stock, par value (in dollars per share)				$ 0.0001		$ 0.0001	$ 0.0001
Net tangible assets				$ 5,000,001
Restriction on redemption of common stock sold (as a percent)				15.00%
Redemption obligation of shares upon non completion of business combination (as a percent)				100.00%
Term to complete business combination				24 months
Number of business days to redeem public shares				10 days
Maximum reduction in interest to pay dissolution expenses				$ 50,000
Annual limit of amount released to the Company to fund working capital requirements				$ 250,000
Redemption price (in dollars per share)				$ 10.00
Working Capital				$ 250,000
Cash Held Outside of Trust Account				622,000	622,000
Interest available				5,900,000
Interest withdrawn from Trust Account				1,448,533	665,756
Working capital deficit				$ 2,400,000
Sponsor
Description of Organization and Business Operations
Offer price (in dollars per unit)				$ 1.50
Common stock, par value (in dollars per share)		$ 0.0001
Proceeds from issuance of common stock to Sponsor		$ 25,000		$ 25,000
Loan from related party	$ 270,531			270,531
Interest withdrawn from Trust Account				$ 1,400,000	$ 666,000
IPO
Description of Organization and Business Operations
Units issued (in units)	$ 25,000,000
Offer price (in dollars per unit)	$ 10.00
Proceeds received from initial public offering	$ 250,000,000
Offering costs	13,060,000
Deferred underwriting commissions charged to equity in connection with the initial public offering	7,875,000
Private Placement Warrants \| Sponsor
Description of Organization and Business Operations
Units issued (in units)	$ 4,333,333
Offer price (in dollars per unit)	$ 1.50
Proceeds received from private placement	$ 6,500,000
Additional warrants available (in warrants)	500,000
Over-Allotment Option
Description of Organization and Business Operations
Underwriting option term	45 days
Offer price (in dollars per unit)	$ 10.00
Number of additional units to be purchased to cover over-allotment	3,750,000

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 622,162	$ 947,098
Prepaid expenses	124,468	158,005
Total current assets	746,630	1,105,103
Cash and marketable securities held in Trust Account	255,880,268	253,019,179
Total assets	256,626,898	254,124,282
Current liabilities:
Accounts payable	28,675	40,774
Accrued expenses	3,125,000	500,379
Franchise tax payable	44,697	158,240
Total current liabilities	3,198,372	699,393
Deferred underwriting commissions	7,875,000	7,875,000
Total liabilities	11,073,372	8,574,393
Commitments and Contingencies
Common stock, $0.0001 par value; 24,055,352 and 24,054,988 shares subject to possible redemption at September 30, 2019 and December 31, 2018, respectively	240,553,520	240,549,880
Stockholders' Equity:
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding
Common stock, $0.0001 par value; 200,000,000 shares authorized; 7,194,648 and 7,195,012 shares issued and outstanding (excluding 24,055,352 and 24,054,988 shares subject to possible redemption) at September 30, 2019 and December 31, 2018, respectively	719	720
Additional paid-in capital	2,910,249	2,913,888
Retained earnings	2,089,038	2,085,401
Total stockholders' equity	5,000,006	5,000,009
Total Liabilities and Stockholders' Equity	$ 256,626,898	$ 254,124,282

Fair Value Measurements (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Fair value measurements, recurring and nonrecurring, valuation techniques
Cash and marketable securities held in Trust Account	$ 255,880,268	$ 253,019,179
Trust account held in cash	1,300	900
Fair value measurements, (Recurring) \| Level 1
Fair value measurements, recurring and nonrecurring, valuation techniques
Cash and marketable securities held in Trust Account	$ 255,880,268	$ 253,019,179

Related Party Transactions (Details) - USD ($)				2 Months Ended	9 Months Ended
Related Party Transactions (Details) - USD ($)	Apr. 02, 2018	Feb. 21, 2018	Dec. 15, 2017	Jan. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Feb. 15, 2018
Related Party Transactions
Shares issued (in shares)					7,194,648		7,195,012
Common stock, par value (in dollars per share)					$ 0.0001		$ 0.0001	$ 0.0001
Minimum period for not to transfer, assign or sell of any shares		30 days
Offer price (in dollars per unit)					$ 10.00
Proceeds received from private placement						$ 6,500,000
Outstanding borrowings under working capital loans					$ 0
Sponsor
Related Party Transactions
Shares issued (in shares)			7,187,500
Common stock, par value (in dollars per share)			$ 0.0001
Proceeds from issuance of common stock to Sponsor			$ 25,000		$ 25,000
Shares subject to forfeiture					937,500
Forfeiture adjusted percentage to issued and outstanding shares					20.00%
Number of shares forfeited	937,500
Minimum period for not to transfer, assign or sell of any shares					1 year
Minimum price for not to transfer, assign or sell of any founder shares					$ 12.00
Number of trading days considered in a period of 30 trading days for minimum price alternative					20 days
Minimum period for considering price per share alternative					150 days
Offer price (in dollars per unit)					$ 1.50
Loan from related party		$ 270,531			$ 270,531
Maximum working capital loans may be converted to warrants					$ 1,500,000
Sponsor \| Private Placement Warrants
Related Party Transactions
Price Per Warrant		$ 1.50
Warrants issued (in warrants)		4,333,333
Proceeds received from private placement		$ 6,500,000
Number of Additional Warrants to be Purchased upon Exercise of Over-allotment		500,000
Issued Price of Additional Warrants		$ 1.50
Proceeds to be received upon additional warrants exercised		$ 750,000
Common stock exercisable for each warrant					1
Exercise price of warrants					$ 11.50
CFO
Related Party Transactions
Founder shares transferred				100,000
Independent directors
Related Party Transactions
Founder shares transferred				30,000
Deerfield Management
Related Party Transactions
Shares issued (in shares)		2,500,000
Price per unit		10.00